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ABSTRACT: 3-(2-Haloacyl)-2-oxazolidinones were shown to react with enals in an asymmetric 
SmI2-promoted Reformatsky reaction to give stereochemically well-defined 3-hydroxy-4-alkenyl- 
and 3-hydroxy-2-methyl-4-alkenyl imides. Chirality transfer of the Evans (S)-oxazolidinone unit 
via a Zimmerman-Traxler-like transition state resulted in Reformatsky products with a relative 
syn-configuration. The absolute configuration of compounds obtained is opposite to the 
corresponding products obtained via aldol addition of boron enolates to enals using the same Evans 
oxazolidinones. 
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  INTRODUCTION 
In 1977 Kagan discovered samarium(II) iodide as a powerful single electron reducing agent, that 
mediates both radical and ionic reactions.1 This finding led to its broad applications in organic 
synthesis. Prominent examples of SmI2-mediated reactions are pinacol-type couplings, radical 
alkene-alkyne couplings, aldol-type reactions, Barbier, Grignard and Reformatsky reactions.2 
While Reformatsky reactions of α-bromo esters and α-bromo ketones in the presence of SmI2 to 
the corresponding β-hydroxy esters have been already reported by Kagan,3 the first intramolecular 
asymmetric variant has been studied by Molander.4 Much later, the first intermolecular asymmetric 
samarium Reformatsky reactions were developed by Fukuzawa utilizing α-bromoacetyl-2-
oxazolidinones as source of chirality.5–7 Skrydstrup employed N-acyloxazolidinones as acyl 
radical equivalents in SmI2-promoted couplings to N-acrylamides.8 In Reformatsky reactions with 
α-haloacetyl-2-oxazolidinones the substrate scope was further extended by Burke towards α-
aminoaldehydes paving the way for pharmacologically relevant isostatine and dolaisoleucine.9 
Despite these impressive results, progress in asymmetric intermolecular samarium Reformatsky 
reactions is still slow,10 in particular enals were only rarely employed as electrophilic substrates.11–
13
 Such stereoselective cross couplings would be interesting, because the resulting β-hydroxy-γ-
alkenyl-ketones (amides, esters or acids) are subunits of natural products such as eremofortin F,14 
stellatolide H,15 stellettapeptins A and B,16 mohangic acids,17 ieodomycin C,18 or largazole19 
(Figure 1). Furthermore, they are valuable synthetic scaffolds for the synthesis of complex target 
molecules, as was exemplified in the total synthesis of pleuraspiroketals A, B,20 (–)-clavosolide A, 
B,21 bistramide K,22 solomonamide,23 azaspirene,24 dolatrienoic acid,7 and ferrulactone.25 The β-
hydroxy-γ-alkenyl-ketone unit has been previously accessed via stereoselective aldol reactions 
using Evans oxazolidinones.26–29 
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Figure 1. Natural compounds or subunits of natural compounds containing the β-hydroxy-γ-
alkenyl-ketone (amide, ester or acid) residue 
Regarding chirality transfer, these studies revealed that the aldol addition of boron enolates 
strongly favoured the syn-aldol products and the stereogenic centre at C-4 of the oxazolidinone 
directed the hydroxy group to the opposite face,21,26,28 while the E- or Z-configuration of the enal 
had almost no influence on the stereochemical outcome of the C–C coupling (Scheme 1, routes a-
c).28 In contrast, the samarium Reformatsky reactions reported by Fukuzawa5 and Burke9 provided 
the β-hydroxyimides lacking an α-substituent with the hydroxy group and the stereodirecting 
isopropyl moiety of the Evans auxiliary positioned on the same side (Scheme 1, routes d,e). Thus, 
it was our intention to probe the suitability of enals as substrates in such samarium Reformatsky 
reactions. We were particularly interested in terpene-derived enals, which might enable the C–C 
coupling with complementary stereocontrol as compared to the boron aldol reaction.28 
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Scheme 1. Selected C–C coupling reactions from the literature and the current work 
 
In addition, we were curious about the chirality transfer to the α-substituent in the N-acyl chain 
(C-2'). In the current manuscript we demonstrate the successful implementation of aliphatic and 
aryl-substituted enals in the SmI2-promoted Reformatsky reaction and elucidate the stereocontrol 
at the α-position. Moreover, by using the Evans oxazolidinone auxiliary with the same 
configuration as in reaction a) in Scheme 1, syn-β-hydroxy-γ-alkenyl-imides are obtained, which 
are stereocomplementary to the boron-enolate-derived aldol products (Scheme 1). The results are 
discussed below. 
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  RESULTS AND DISCUSSION 
Reformatsky Reactions of Terpene Enals (E)- and (Z)-5. Initially, Reformatsky reactions 
were carried out with 3-(2-haloacetyl)oxazolidinones 7a,b30,31 and geranial (E)-5 and neral (Z)-
5.31,32 The results are summarized in Table 1. In a preliminary experiment geranial (E)-5 and 3-(2-
bromoacetyl)oxazolidinone 7a were added simultaneously to a cooled solution of 2.2 equiv SmI2 
in THF at –78 °C, and the reaction mixture was stirred for 1 h (method A). After aqueous workup 
and chromatographic purification, compound (3'R,4'E)-13a was obtained as a single diastereomer 
albeit in a low yield of 32% (entry 1). In a similar fashion neral (Z)-5 yielded one diastereomeric 
product (3'R,4'Z)-13a in 23% yield (entry 2). Monitoring of these reactions by TLC revealed 
several spots. The ability of SmI2 to reduce carbonyl compounds and to promote reductive pinacol-
type carbonyl couplings or polymerizations is well known.2 Presumably, reduction of terpene enals 
and coupling of radical intermediates compete with the SmI2-mediated Reformatsky reaction 
leading to the consumption of SmI2 and formation of byproducts. Hence, the reaction was 
modified, and a solution of SmI2 in THF was cooled to –78 °C prior to addition of a solution of 3-
(2-bromoacetyl)oxazolidinone 7a in THF. The resulting mixture was stirred for 5 min in the dark 
to permit formation of the Sm(III) enolate, followed by slow addition of the enal 5 (method B). 
After 0.5 h, TLC indicated almost complete conversion. The reaction mixture was stirred for a 
further 0.5 h followed by workup. Under these conditions the Reformatsky reactions proceeded 
much cleaner with less byproducts. Geranial (E)-5 gave the diastereomers (3'R,4'E)-13a and 
(3'S,4'E)-13a in 73% and 6% yield (dr 92 : 8, entry 3), while neral (Z)-5 yielded (3'R,4'Z)-13a and 
(3'S,4'Z)-13a in 71% and 7% yield (dr 91 : 9, entry 4). Both yields and diastereoselectivities were 
not affected by the configuration of the enal C=C double bond. 
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Table 1. SmI2-Mediated Reformatsky Reaction of 3-(Haloacetyl)oxazolidinones 7a,b with 
Terpene Enals (E)-5 and (Z)-5a,b 
 
entry 7 enal T (°C) method isolated yield (%) ratioc 
1 7a (E)-5 –78 A (3'R,4'E)-13a 32 100 : 0 
2 7a (Z)-5 –78 A (3'R,4'Z)-13a 23 100 : 0 
3 7a (E)-5 –78 B (3'R,4'E)-13a 
(3'S,4'E)-13a 
73 
 6 
 92 : 8 
4 7a (Z)-5 –78 B (3'R,4'Z)-13a 
(3'S,4'Z)-13a 
71 
 7 
 91 : 9 
5 7a (E)-5 –100 B (3'R,4'E)-13a 59  90 : 10 
6 7a (Z)-5 –100 B (3'R,4'Z)-13a 54  90 : 10 
7 7b (E)-5 –78 B (3'R,4'E)-13a 48  89 : 11 
8 7b (Z)-5 –78 B (3'R,4'Z)-13a 43  90 : 10 
9 7b (E)-5 –100 B (3'R,4'E)-13a 56  90 : 10 
10 7b (Z)-5 –100 B (3'R,4'Z)-13a 50  91 : 9 
aSmI2 (0.1 M, THF). bMethod A: simultaneous addition of enal and 
oxazolidinone to a cooled solution of SmI2 in THF; method B: 1) ad-
dition of oxazolidinone to a cooled solution of SmI2 in THF; 2) equi-
libration for 5 min; 3) addition of enal. cDiastereomeric ratios were de-
termined by isolation. 
 8
Lowering the temperature to –100 °C led to decreased yields, but comparable diastereomeric 
ratios, i.e. (3'R,4'E)-13a (59%, dr 90 : 10) and (3'R,4'Z)-13a (54%, dr 90 : 10) (entries 5, 6). The 
decreased reaction rate is probably due to the poor solubility of the Sm(III) enolate at –100 °C. It 
should be noted that additives such as HMPA enhance the reduction potential of SmI2.2b,d,33 
However, we avoided using toxic additives in the reaction. Alternatively, SmI2 might lead to 
reductive cleavage of the oxazolidinone auxiliary as recently reported by Frontier.34  
When the corresponding 3-(2-chloroacetyl)oxazolidinone 7b was employed under these con-
ditions, yields were generally lower than those with 3-(2-bromoacetyl)oxazolidinone 7a, but in-
creased with decreasing temperature. The diastereoselectivity, however, remained unchanged 
(dr ~ 90 : 10) (Table 1, entries 7, 9 and 8, 10). 
To investigate the reactivity of secondary halides and the effect of chirality at the halide on the 
outcome of the Reformatsky reaction, 3-(2-bromopropanoyl)oxazolidinone 1231,35 was employed 
in a series of experiments (Table 2). First, diastereomeric mixtures of 12 (dr 67 : 33) were reacted 
with geranial (E)-5 and neral (Z)-5, respectively, under the conditions of method B described 
above, providing diastereomeric mixtures of (E)-14a (dr 63 : 21 : 16) and (Z)-14a (dr 71 : 20 : 9), 
respectively, from which the major diastereomers (2'R,3'S,4'E)-14a and (2'R,3'S,4'Z)-14a could be 
isolated in 55% and 59%, respectively (entries 1 and 2).  
Because of the rapid epimerization of 3-(2-bromopropanoyl)oxazolidinone,35 the diastereomers 
(2'R)-12 and (2'S)-12 were separated by chromatography and immediately used for the reactions. 
However, diastereomeric ratios and yields did not change markedly (entries 3–6), suggesting that 
neither rate nor selectivity forming step is affected by the stereogenic centre at the 2-bromo-
propanoyl unit. 
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Table 2. SmI2-Mediated Reformatsky Reaction of 3-(2-Bromopropanoyl)oxazolidinone 12 
with Terpene Enals (E)-5 and (Z)-5a,b 
 
entry 12 enal yieldc (%) ratio (R,S):(S,R):(R,R)d 
1 12 (67:33) (E)-5 (2'R,3'S,4'E)-14a 55 (E)-14a 63 : 21 : 16 
2 12 (67:33) (Z)-5 (2'R,3'S,4'Z)-14a 59 (Z)-14a 71 : 20 :   9 
3 (2'R)-12 (E)-5 (2'R,3'S,4'E)-14a 52 (E)-14a 63 : 22 : 15 
4 (2'R)-12 (Z)-5 (2'R,3'S,4'Z)-14a 59 (Z)-14a 70 : 19 : 11 
5 (2'S)-12 (E)-5 (2'R,3'S,4'E)-14a 53 (E)-14a 62 : 22 : 16 
6 (2'S)-12 (Z)-5 (2'R,3'S,4'Z)-14a 57 (Z)-14a 71 : 19 : 10 
aSmI2 (0.1 M, THF). bMethod B: 1) addition of oxazolidinone to a cooled solution 
of SmI2 in THF; 2) equilibration for 5 min; 3) addition of enal. cIsolated yields; 
diastereomeric ratios were determined by isolation. d(2'S,3'S)-diastereomers were 
not observed. 
Assignment of Relative and Absolute Configuration of Reformatsky Products 13, 14 and 
Proposed Mechanism. The absolute configuration at the C-3' atom in the Reformatsky products 
(4'E)-13a and (4'Z)-13a was determined by applying Mosher’s method.36 Adopting a procedure 
reported by Laschat28 geranial-derived Reformatsky product (4'E)-13a was esterified with Mosher 
acyl chloride (R)- and (S)-MTPACl to afford the corresponding (S)- and (R)-MTPA esters (S)-15a 
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and (R)-15a in 85 and 84% yield, respectively (Scheme 2). In an analogous fashion (S)- and (R)-
MTPA esters (S)-15b and (R)-15b were prepared from neral-derived Reformatsky products (4'Z)-
13a in 70% and 80%, respectively. 
Scheme 2. Conversion of Reformatsky Products 13a and 14a into the Corresponding Mosher 
Esters (R)- and (S)-15a,b and (R)- and (S)-16a,b, respectively 
 
Analysis of the differences in the chemical shifts36 between (R)- and (S)-Mosher ester in the 1H 
NMR indicated the absolute configuration at C-3' as (3'R) for both (E)-geranial- and (Z)-neral-
derived Mosher esters (S)-15a, (R)-15a and (S)-15b, (R)-15b [Table S1, see Supporting Informa-
tion (SI)]. Following the same procedure, the Mosher esters 16 of diastereomerically pure (E)-14a 
and (Z)-14a were prepared (Scheme 2). From the chemical shift differences between (R) and (S) 
Mosher ester the (3'S) configuration at C-3' was assigned for (E)-geranial- and (Z)-neral-derived 
Mosher esters (S)-16a, (R)-16a and (S)-16b, (R)-16b, respectively (Table S2, SI).  
In order to assign the configuration at C-2', Reformatsky products (E)-14a, (Z)-14a were 
converted into the conformationally locked cyclic acetals (E)- and (Z)-18 following a known 
procedure28 (Scheme 3).  
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Scheme 3. Synthesis of Acetals (E)- and (Z)-18 from Reformatsky Products (E)- and (Z)-14a 
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The chiral auxiliary was removed from (E)- and (Z)-14a in a (100 : 1) mixture of THF / MeOH 
with LiBH4 in THF to yield the respective diols (E)- and (Z)-17 in 64% and 60% after workup and 
chromatographic purification. Diols 17 were then reacted with 2,2-dimethoxypropane and PPTS 
in acetone followed by workup and chromatography to provide acetals (E)- and (Z)-18 in 90% and 
88%, respectively (Scheme 3). 
NOESY correlations were used to assign the relative configuration at C-2'/C-3'.28 A strong NOE 
between 2'-H and 3'-H was observed for acetal (E)-18, confirming a syn-configuration of the 
stereogenic centers C-2'/C-3'. Analogous results revealed a syn-configuration of the stereogenic 
centers C-2'/C-3' in acetal (Z)-18. Thus, irrespective of the geometry of the C=C double bond for 
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both acetals (E)- and (Z)-18 a (2'S,3'S)-configuration was found. Consequently, the major 
diastereomers (E)- and (Z)-14a are (2'R,3'S) configurated. 
However, this procedure could not be used for minor diastereomers of 14a because of their very 
low amounts. Hence, the absolute and relative configuration at C-2'/C-3' for these products was 
proposed considering the transition state geometries published by Fukuzawa.5a In agreement with 
the evidence reported by Evans and coworkers, enolization of N-acyl oxazolidinones leads to the 
selective formation of (Z)-metal enolates.37 It is therefore reasonable to assume that this geometry 
is involved also in case of samarium enolates. According to Fukuzawa,5a asymmetric samarium(II) 
iodide-promoted Reformatsky reactions proceed via formation of a chelated transition state. 
Adapting this model to our reaction we propose that samarium coordinates both the enolate oxygen 
and the carbonyl group of the oxazolidinone auxiliary as well as the oxygen of the incoming 
aldehyde (Scheme 4).  
Scheme 4. Proposed Mechanism of Diastereomer Formation 
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Depending on the geometry of the enolate double bond and the relative topicity of enolate and 
aldehyde four different transition state geometries A–D are possible. Re face attack at the enal 
seems to be favoured (transition states A, C), because steric interactions between the oxazolidinone 
isopropyl group and the enolate methyl group are minimized as compared to transition states B, 
D. The observed stereochemistry of the main diastereomers 14 is fully consistent with this 
hypothesis. The disfavored Si face attack at the enals (transition state B) could yield the minor syn 
diastereomers. Magnesium(II) chloride-catalyzed aldol reactions of N-acyl oxazolidinones with 
non-enolizable aldehydes were reported to afford selectively the anti adducts. The authors suggest 
the involvement of a magnesium-chelating boat transition structure.38 Assuming a similar structure 
in the case of samarium enolates could lead to the formation of the minor anti diastereomer. 
However, from preliminary DFT calculations a boat transition state seems to be unlikely because 
in such highly strained geometry the chelating coordination of the samarium enolate by the 
oxazolidinone carbonyl group is not possible. 
The mechanistic proposal is supported by the observation that (2E,6E)-8-[(4-methoxybenzyl)oxy]-
3-(methoxymethyl)-7-methylocta-2,6-dienal 3631 carrying an allylic methoxy group did not react 
with 3-(2-bromoacetyl)oxazolidinone 7a (Scheme S5, SI). Presumably, the allylic methoxy group 
in close proximity to the reactive site of the enol interfered with the chelate complex between 
Sm(III) enolate and the oxazolidinone carbonyl, thus suppressing the C–C bond forming step. 
Reformatsky Reaction with Aryl- and Alkyl-substituted Enals. In order to further broaden 
the scope of the samarium Reformatsky reaction, a series of aryl-substituted enals 2a–e31,39,40 was 
investigated using method B described above (Table 3).  
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Table 3. SmI2-Mediated Reformatsky Reaction of N-(2-Bromoacetyl)- and N-(2-Bromopro-
pionyl)oxazolidinone 7a, 12 with Enals 2a–ea,b 
 
entry 7a, 12 2 Ar 
R1 
           yield c (%) ratio 13 
(R):(S) 
ratio 14 
(R,S):(S,R):(R,R):(S,S) 
1 7a 2a H (3'R)-13b 51 96 : 4 – 
2 7a 2b OMe (3'R)-13c 30 98 : 2 – 
3 7a 2c Me (3'R)-13d 22 99 : 1 – 
4 7a 2d Cl (3'R)-13e 33 94 : 6 – 
5 7a 2e NO2 (3'R)-13f 24 – – 
6 12 2a H (2'R,3'S)-14b 92 – 92 :   5 : 2 : 1 
7 12 2b OMe (2'R,3'S)-14c 63 – 85 : 15 : 0 : 0 
8 12 2c Me (2'R,3'S)-14d 30 – 93 :   6 : 1 : 0 
9 12 2d Cl (2'R,3'S)-14e 34 – 86 :   9 : 3 : 2 
10 12 2e NO2 (2'R,3'S)-14f 52 – 94 :   4 : 2 : 0 
aSmI2 (0.1 M, THF). bMethod B: 1) addition of oxazolidinone to a cooled solution of 
SmI2 in THF; 2) equilibration for 5 min; 3) addition of enal. cIsolated yields; 
diastereomeric ratios were determined by isolation.  
Reaction of 3-(2-bromoacetyl)oxazolidinone 7a with cinnamic aldehyde 2a under the conditions 
described above yielded a (96 : 4) diastereomeric mixture of the Reformatsky products 13b in 51% 
yield, from which the major diastereomer was (3'R)-13b (entry 1). Under similar conditions p-
substituted cinnamic aldehydes 2b–e gave poorer yields of 22–33%, but the diastereomeric ratios 
were only little affected by the electronic influence of the p-substituent (dr 94 : 6 up to 99 : 1) 
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(entries 2–4). The Reformatsky reaction of 2e proceeded to 13f, but attempts to separate the 
diastereomers by HPLC failed (entry 5).  
Next, a series of experiments with 3-(2-bromopropionyl)oxazolidinone 12 was carried out. As can 
be seen from Table 3, cinnamic aldehyde 2a yielded products 14b in 92% in a diastereomeric ratio 
of (92 : 5 : 2 : 1) and the major isomer was assumed to be (2'R,3'S)-14b (entry 6). The other enals 
2b–e gave Reformatsky products 14c–f in yields of 30–63% (entries 7–10), which were generally 
higher as compared to 13c–f. Good diastereoselectivities ranging from (dr 85 : 15 : 0 : 0) up to 
(94 : 4 : 2 : 0) were obtained for 14c–f. All diastereomeric ratios for compounds 13b–f and 14b–f 
were determined by analytical HPLC. In the case of derivatives 13d,e and 14c,d, the separation 
succeeded by HPLC on chiral stationary phases. 
The minor anti (2'S,3'S)-diastereomer of 14b and 14e could be detected (entries 6 and 9) in contrast 
to the other products 14c,d,f and the terpene enal derived (E)- and (Z)-14a (Table 2). 
In an analogous manner to Reformatsky products 14a (Scheme 2), pure major diastereomer 14b 
was reacted with (R)- and (S)-MTPACl to yield the corresponding (S)- and (R)-Mosher esters 16c31 
(Table S3, SI). The NMR analysis confirmed for both (R)- and (S)-16c the (S)-configuration at C-
3'. NOESY 1H NMR experiments were performed for the assumed major diastereomer (2'S,3'R)-
14b revealing a syn-configuration (Figure S1, SI), which is in good accordance with the transition 
state described above and thus, the (R)-configuration at C-2' was concluded. The two other 
diastereomers (2'S,3'S)-14b and (2'R,3'R)-14b could not be isolated and assigned due to their small 
amount. For the major diastereomers 14c–f the (2'R,3'S)-configuration was assumed as well. 
When crotonic aldehyde 2f was reacted with oxazolidinone 7a, product 13g was isolated in 54% 
(dr 90 : 10). Analogously, cyclopentene-1-carbaldehyde 2g yielded Reformatsky product 13h in 
56% (dr 59 : 41) (Scheme 5).  
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Scheme 5. SmI2-Mediated Reformatsky Reaction of Aldehydes 2a,f,g with Oxazolidinones 
7a, 12 and 20a 
 
a
 The diastereomers of 13 and 14 could not be clearly assigned. 
Under the same conditions the Reformatsky reaction of both 2f and 2g with oxazolidinone 12 
resulted in diastereomeric mixtures 14g (85 : 12 : 3) and 14h (52:35:7:6) in isolated yields of 90% 
and 78%, respectively, which, however, could not be completely separated and assigned by HPLC. 
To further probe the substrate scope of the Reformatsky reaction 3-(2-chloroacyl)oxazolidinone 
2031 carrying a quaternary carbon and a free alcohol moiety adjacent to the α-carbon was treated 
with SmI2 and cinnamic aldehyde 2a (Scheme 5). Gratifyingly, the desired product syn,syn-21 was 
isolated as a single diastereomer, albeit in 27% yield. Thus, even under these sterically demanding 
conditions the syn,syn-diastereomer was strongly favored.  
  CONCLUSION 
Enals have been employed in asymmetric samarium Reformatsky reactions with 3-(2-haloacyl)-2-
oxazolidinones 7a,b, 12 providing access to stereochemically well-defined 3-hydroxy-4-alkenyl- 
and 3-hydroxy-2-methyl-4-alkenyl imides (13, 14). Chirality transfer of the Evans (S)-
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oxazolidinone unit via a Zimmerman-Traxler-like transition state resulted in the (R)-configuration 
of the hydroxy group in products 13a–f in case of 3-(2-haloacetyl)oxazolidinones 7a,b. When 3-
(2-bromopropionyl)oxazolidinone 12 was employed, the (S)-oxazolidinone moiety led to the 
preferred formation of the (2'R,3'S)-configuration of the aldol unit, thus giving a relative syn-
configuration in Reformatsky products 14a–f. Moreover, their absolute configuration is opposite 
to the corresponding products obtained via aldol addition of boron enolates to enals using (S)-
configurated oxazolidinones. Thus, the SmI2-promoted Reformatsky reaction of enals not only 
demonstrates the power of the Evans auxiliary to effectively control the stereochemistry of C–C 
cross coupling reactions, but also provides a complementary entry towards syn-3-hydroxy-2-
methyl-4-alkenyl imides, yielding the mirror images of boron-enolate-derived aldol products or 
titanium-enolate derived products.41 The synthetic utility of this novel methodology can now be 
further explored in the synthesis of complex target molecules. 
  EXPERIMENTAL SECTION 
All reactions were performed under nitrogen atmosphere using common Schlenk technique. All 
reagents were used as purchased unless otherwise stated. Solvents were purified and dried by 
standard procedures prior to use. The SmI2 was purchased in a sealed bottle as a 0.1 M solution in 
THF and could be stored in the fridge for several weeks after opening without decomposing. NMR 
spectra were recorded on 300, 400, 500 and 700 MHz spectrometers at room temperature with 
TMS as an internal standard. Signals in 1H and 13C NMR spectra were assigned using COSY, 
HSQC, HMBC, and NOESY techniques. IR spectra were recorded on an FT-IR spectrometer at 
room temperature. Mass spectra (MS) were recorded using the ESI-TOF technique. Optical 
rotation was recorded at room temperature (Na-D-line, 589 nm). Diastereomeric ratios were 
determined by analytical HPLC using a variable wave detector (180–800 nm), performed on a MS-
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Analytical Kromasil column (250 × 4.6 mm, 100 Si 5 μm), a Chiralcel OJ-H column 
(150 × 4.6 mm, 5 µm) or a Chiralcel OD-H column (250 × 4.6 mm, 5 µm). For preparative HPLC 
a MZ-Analytical Orbit column (250 × 20 mm, 100 Sil 5 µm) was used. Thin layer chromatography 
was performed on silica gel 60 F254 precoated aluminium plates. Column chromatography was 
carried out using silica gel (40–60 µm) with solvents distilled prior to use.  
General Procedure for the Samarium-Mediated Reformatsky Reaction of N-Haloacyl-2-
oxazolidinones with Enals (GP1). To a solution of SmI2 (0.1 M in THF, 2.20 equiv) at –78 °C 
was added dropwise a solution of the respective 7a,b, 12 or 20 (1.0 equiv) in abs. THF (3 mL), 
and the reaction mixture was stirred for 5 min followed by dropwise addition of a solution of the 
appropriate enal 5 or 2 (1.2 equiv) in abs. THF (3 mL). The reaction mixture was stirred at  
–78 °C for 1 h. Then a satd solution of NH4Cl–H2O (20 mL) was added at –78 °C, and the reaction 
mixture was allowed to warm to room temperature. The layers were separated and the aqueous 
layer was extracted with EtOAc (3 × 15 mL). The combined organic layers were washed with a 
satd solution of Na2S2O3, dried (MgSO4) and concentrated under vacuum. The residue was purified 
by chromatography on SiO2. 
(4S)-3-[(3R,4E)- and (3S,4E)-3-Hydroxy-5,9-dimethyldeca-4,8-dienoyl)-4-isopropyl-1,3-oxa-
zolidin-2-one [(3'R,4'E)- and (3'S,4'E)-13a]. Chromatography (PE/EtOAc 2:1) afforded (3'R,4'E)-
13a (236 mg, 0.73 mmol, 73%, purity 95% 1H NMR, Rf = 0.32) and (3'S,4'E)-13a (20 mg, 
60 μmol, 6%, purity 95% 1H NMR, Rf = 0.38) as colorless oils. (3'R,4'E)-13a: 20D]α[ = +33.5 (c = 
1.2 in CH2Cl2); 1H NMR (400 MHz, CDCl3) δ (ppm) = 0.88 (d, J = 6.9 Hz, 3H, 5’-H or 6’-H), 
0.92 (d, J = 6.9 Hz, 3H, 5’-H or 6’-H), 1.59 (s, 3H, 10-H or 11-H), 1.67 (s, 3H, 10-H or 11-H), 
1.71 (s, 3H, 12H), 1.95-2.14 (m, 4H, 6-H, 7-H), 2.32-2.43 (m, 1H, 4’-H), 3.06-3.16 (m, 2H, 2-H), 
4.20-4.30 (m, 2H, 2’-H, 3’-Ha), 4.39-4.48 (m, 1H, 3’-Hb), 4.85-4.91 (m, 1H, 3-H), 5.04-5.11 (m, 
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1H, 8-H), 5.25 (dd, J = 8.5 Hz, 1.1 Hz, 1H, 4-H); 13C{1H} NMR (100 MHz, CDCl3) δ (ppm) = 
14.9 (C-6’), 16.8 (C-5’), 17.8 (C-12), 18.1 (C-10, C-11), 25.8 (C-10), 26.5 (C-7), 28.6 (C-4’), 39.6 
(C-2), 43.0 (C-6), 58.6 (C-3), 63.8 (C-3’), 65.2 (C-2’), 124.0 (C-8), 125.5 (C-4), 131.9 (C-9), 139.5 
(C-5), 154.1 (C-1’), 172.3 (C-1); FT-IR (ATR):  = 3485 (w), 2964 (m), 2920 (m), 1777 (vs), 1696 
(s), 1486 (w), 1441 (w), 1372 (s), 1301 (m), 1202 (s), 1141 (m), 1120 (m), 1104 (m), 1058 (s), 
1020 (s), 928 (w), 814 (w), 774 (m), 753 (m), 713 (m), 640 (m), 590 (w), 526 (w) cm–1; HRMS 
(ESI) m/z: [M+Na]+ Calcd for C18H29NO4Na 346.1989; Found 346.1996. (3'S,4'E)-13a: 1H NMR 
(400 MHz, CDCl3) δ (ppm) = 0.88 (d, J = 6.9 Hz, 3H, 5’-H or 6’-H), 0.93 (d, J = 6.9 Hz, 3H, 5’-
H or 6’-H), 1.59 (s, 3H, 10-H or 11-H), 1.67 (s, 3H, 10-H or 11-H), 1.71 (s, 3H, 12-H), 1.95-2.14 
(m, 4H, 6-H, 7-H), 2.32-2.43 (m, 1H, 4’-H), 3.06-3.16 (m, 2H, 2-H), 4.20-4.30 (m, 2H, 2’-H, 3’-
Ha), 4.48-4.41 (m, 1H, 3’-Hb), 4.83-4.92 (m, 1H, 3-H), 5.07-5.15 (m, 1H, 8-H), 5.28 (d, J = 8.9 
Hz, 1H, 4-H); 13C{1H} NMR (100 MHz, CDCl3) δ (ppm) = 14.9 (C-6’), 16.8 (C-5’), 17.8 (C-12), 
18.1 (C-10, C-11), 25.8 (C-10), 26.5 (C-7), 28.6 (C-4’), 39.6 (C-2), 43.0 (C-6), 58.6 (C-3), 63.8 
(C-3’), 65.2 (C-2’), 124.0(C-8), 125.5 (C-4), 131.9 (C-9), 139.5 (C-5), 154.1 (C-1’), 172.3 (C-1); 
FT-IR (ATR):  = 3495 (w), 2964 (w), 2925 (w), 2976 (w), 1778 (s), 1699 (m), 1447 (w), 1386 
(s), 1373 (s), 1302 (m), 1204 (s), 1179 (m), 1143 (w), 1120 (w), 1102 (w), 1058 (m), 1020 (m), 
972 (w), 845 (w), 775 (w), 754 (w), 713 (w), 640 (w), 587 (w), 527 (w), 454 (w) cm–1; HRMS 
(ESI) m/z: [M+Na]+ Calcd for C18H29NO4Na 346.1989; Found 346.1973. 
(4S)-3-[(3R,4Z)- and (3S,4Z)-3-Hydroxy-5,9-dimethyldeca-4,8-dienoyl)-4-isopropyl-1,3-oxa-
zolidin-2-one [(3'R,4'Z)- and (3'S,4'Z)-13a]. Chromatography (PE/EtOAc 2 : 1) afforded (3'R,4'Z)-
13a (230 mg, 0.71 mmol, 71%, purity 95% 1H NMR, Rf = 0.32) and (3'S,4'Z)-13a (21 mg, 0.07 
mmol, 7%, purity 90% 1H NMR, Rf = 0.35) as coloress oils. (3'R,4'Z)-13a: 20D]α[  = +38.7 (c = 1.0 
in CH2Cl2); 1H NMR (400 MHz, CDCl3) δ (ppm) = 0.88 (d, J = 6.9 Hz, 3H, 5’-H or 6’-H), 0.92 
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(d, J = 7.0 Hz, 3H, 5’-H or 6’-H), 1.60 (s, 3H, 10-H or 11-H), 1.68 (s, 3H, 10-H or 11-H), 1.73 (s, 
3H, 12-H), 2.03-2.20 (m, 4H, 6-H, 7-H), 2.33-2.44 (m, 1H, 4’-H), 3.09-3.14 (m, 2H, 2-H), 4.19-
4.32 (m, 2H, 2’-H, 3’-Ha), 4.41-4.49 (m, 1H, 3’-Hb), 4.85-4.90 (m, 1H, 3-H), 5.08-5.15 (m, 1H, 8-
H), 5.28 (d, J = 8.9 Hz, 1H, 4-H); 13C{1H} NMR (100 MHz, CDCl3) δ (ppm) = 14.9 (C-6’), 16.8 
(C-5’), 17.8 (C-12), 18.1 (C-10, C-11), 25.8 (C-10), 26.5 (C-7), 28.6 (C-4’), 39.6 (C-2), 43.0 (C-
6), 58.6 (C-3), 63.8 (C-3’), 65.2 (C-2’), 124.0 (C-8), 125.5 (C-4), 131.9 (C-9), 139.5 (C-5), 154.1 
(C-1’), 172.3 (C-1); FT-IR (ATR):  = 3495 (w), 2964 (w), 2925 (w), 2976 (w), 1778 (s), 1699 
(m), 1447 (w), 1386 (s), 1373 (s), 1302 (m), 1204 (s), 1179 (m), 1143 (w), 1120 (w), 1102 (w), 
1058 (m), 1020 (m), 972 (w), 845 (w), 775 (w), 754 (w), 713 (w), 640 (w), 587 (w), 527 (w), 454 
(w) cm–1; HRMS (ESI) m/z: [M+Na]+ Calcd for C18H29NO4Na 346.1989; Found 346.1988. 
(3'S,4'Z)-13a: 1H NMR (400 MHz, CDCl3) δ (ppm) = 0.88 (d, J = 6.9 Hz, 3H, 5’-H or 6’-H), 0.93 
(d, J = 6.9 Hz, 3H, 5’-H or 6’-H), 1.59 (s, 3H, 10-H or 11-H), 1.67 (s, 3H, 10-H or 11-H), 1.71 (s, 
3H, 12-H), 1.95-2.14 (m, 4H, 6-H, 7-H), 2.32-2.43 (m, 1H, 4’-H), 3.06-3.16 (m, 2H, 2-H), 4.20-
4.30 (m, 2H, 2’-H, 3’-Ha), 4.48-4.41 (m, 1H, 3’-Hb), 4.83-4.92 (m, 1H, 3-H), 5.07-5.15 (m, 1H, 8-
H), 5.28 (d, J = 8.9 Hz, 1H, 4-H); 13C{1H} NMR (100 MHz, CDCl3) δ (ppm) = 14.9 (C-6’), 16.8 
(C-5’), 17.8 (C-12), 18.1 (C-10, C-11), 25.8 (C-10), 26.5 (C-7), 28.6 (C-4’), 39.6 (C-2), 43.0 (C-
6), 58.6 (C-3), 63.8 (C-3’), 65.2 (C-2’), 124.0(C-8), 125.5 (C-4), 131.9 (C-9), 139.5 (C-5), 154.1 
(C-1’), 172.3 (C-1); FT-IR (ATR):  = 3495 (w), 2964 (w), 2925 (w), 2976 (w), 1778 (s), 1699 
(m), 1447 (w), 1386 (s), 1373 (s), 1302 (m), 1204 (s), 1179 (m), 1143 (w), 1120 (w), 1102 (w), 
1058 (m), 1020 (m), 972 (w), 845 (w), 775 (w), 754 (w), 713 (w), 640 (w), 587 (w), 527 (w), 454 
(w) cm–1; HRMS (ESI) m/z: [M+Na]+ Calcd for C18H29NO4Na 346.1989; Found 346.2006. 
(4S)-3-[(4E)-3-Hydroxy-2,5,9-trimethyldeca-4,8-dienoyl)-4-isopropyl-1,3-oxazolidin-2-one 
[(E)-14a]. Chromatography (PE/EtOAc 2 : 1) afforded (3'R,4'E)-14a (46.1 mg, 0.14 mmol, 14%, 
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purity 95% 1H NMR, Rf = 0.37), (2'R,3'S,4'E)-14a (184 mg, 0.55 mmol, 55%, purity 95% 1H 
NMR, Rf = 0.28) and (4'E)-14a (60.6 mg, 0.18 mmol, 18%, purity 90% 1H NMR, Rf = 0.20) as 
colorless oils. (2'R,3'S,4'E)-14a: 20D]α[ = +43.6 (c = 1.0 in CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 
(ppm) = 0.86 (d, J = 7.0 Hz, 3H, 5’-H or 6’-H), 0.91 (d, J = 7.0 Hz, 3H, 5’-H or 6’-H), 1.19 (d, J 
= 6.9 Hz, 3H, 13-H), 1.60 (s, 3H, 10-H or 11-H), 1.68 (s, 3H, 10-H or 11-H), 1.70 (s, 3H, 12-H), 
1.96-2.14 (m, 4H, 6-H, 7-H), 2.26-2.42 (m, 1H, 4’-H), 3.94-4.04 (m, 1H, 2-H), 4.17-4.31 (m, 2H, 
2’-H, 3’-Ha), 4.16-4.32 (m, 1H, 3’-Hb), 4.42-4.49 (m, 1H, 3-H), 5.01-5.11 (m, 1H, 8-H), 5.22 (dd, 
J = 8.7 Hz, 1.1 Hz, 1H, 4-H); 13C{1H} NMR (100 MHz, CDCl3) δ (ppm) = 11.9 (C-13), 14.8 (C-
6’), 17.0 (C-5’), 17.8 (C-12), 18.1 (C-10, C-11), 25.8 (C-10), 26.5 (C-7), 28.7 (C-4’), 39.9 (C-6), 
43.1 (C-2), 58.8 (C-3), 63.4 (C-3’), 69.8 (C-2’), 124.0 (C-8), 125.7 (C-4), 131.9 (C-9), 140.4 (C-
5), 154.3 (C-1’), 175.9 (C-1); FT-IR (ATR):  = 3496 (w), 2965 (m), 2926 (m), 2878 (w), 1775 
(vs), 1697 (s), 1487 (w), 1453 (w), 1375 (s), 1300 (m), 1203 (vs), 1143 (w), 1120 (m), 1101 (m), 
1054 (w), 1015 (w), 989 (m), 954 (m), 904 (w), 818 (w), 776 (w), 709 (w), 640 (w), 537 (w), 441 
(w) cm–1; HRMS (ESI) m/z: [M+Na]+ Calcd for C19H31NO4Na 360.2145; Found 360.2155. 
(3'R,4'E)-14a: 20D]α[ = +42.7 (c = 1.0 in CH2Cl2); 1H NMR (400 MHz, CDCl3) δ (ppm) = 0.89 (d, 
J = 6.9 Hz, 3H, 5’-H or 6’-H), 0.96 (d, J = 6.9 Hz, 3H, 5’-H or 6’-H), 1.08 (d, J = 6.9 Hz, 3H, 13-
H), 1.60 (s, 3H, 10-H or 11-H), 1.67 (s, 3H, 10-H or 11-H), 1.70 (s, 3H, 12-H), 1.95-2.16 (m, 4H, 
6-H, 7-H), 2.34-2.50 (m, 1H, 4’-H), 3.91 (dq, J = 13.8 Hz, 6.9 Hz, 1H, 2-H), 4.19-4.32 (m, 2H, 2’-
H, 3’-Ha), 4.16-4.32 (m, 1H, 3’-Hb), 4.40-4.51 (m, 1H, 3-H), 5.01-5.12 (m, 1H, 8-H), 5.19 (d, J = 
8.3 Hz, 4-H); 13C{1H} NMR (100 MHz, CDCl3) δ (ppm) = 14.2 (C-13), 14.7 (C-6’), 17.0 (C-5’), 
17.8 (C-12), 18.1 (C-10, C-11), 25.8 (C-10), 26.5 (C-7), 28.6 (C-4’), 39.8 (C-6), 44.2 (C-2), 59.1 
(C-3), 63.4 (C-3’), 71.9 (C-2’), 124.0 (C-8), 125.7 (C-4), 132.0 (C-9), 140.9 (C-5), 154.5 (C-1’), 
176.7 (C-1); FT-IR (ATR):  = 3501 (w), 2966 (m), 2924 (m), 2878 (w), 1775 (vs), 1698 (s), 1487 
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(w), 1454 (m), 1383 (vs), 1301 (m), 1251 (m), 1202 (vs), 1142 (m), 1121 (m), 1107 (m), 1081 (m), 
1054 (m), 990 (s), 954 (m), 901 (w), 817 (w), 775 (w), 760 (w), 709 (w), 636 (w), 530 (w), 462 
(w) cm–1; HRMS (ESI) m/z: [M+Na]+ Calcd for C19H31NO4Na 360.2145; Found 360.2162. (4'E)-
14a: 20D]α[ = +38.3 (c = 1.2 in CH2Cl2); 1H NMR (400 MHz, CDCl3) δ (ppm) = 0.87 (d, J = 6.9 Hz, 
3H, 5’-H or 6’-H), 0.91 (d, J = 6.9 Hz, 3H, 5’-H or 6’-H), 1.10 (d, J = 7.0 Hz, 3H, 13-H), 1.58 (s, 
3H, 10-H or 11-H), 1.65 (s, 3H, 10-H or 11-H), 1.68 (s, 3H, 12-H), 1.97-2.15 (m, 4H, 6-H, 7-H), 
2.29-2.38 (m, 1H, 4’-H), 3.82 (dq, J = 14.1 Hz, 7.0 Hz, 1H, 2-H), 4.13-4.30 (m, 2H, 2’-H, 3’-Ha), 
4.44-4.58 (m, 2H, 3-H, 3’-Hb), 4.99-5.09 (m, 1H, 8-H), 5.16 (d, J = 9.1 Hz, 1H, 4-H); 13C{1H} 
NMR (100 MHz, CDCl3) δ (ppm) = 14.7 (C-13), 14.9 (C-6’), 16.9 (C5’), 17.8 (C-12), 18.0 (C-10, 
C-11), 25.5 (C-10), 26.4 (C-7), 28.7 (C-4’), 39.7 (C-6), 44.5 (C-2), 58.6 (C-3), 63.6 (C-3’), 76.1.8 
(C-2’), 123.9 (C-8), 125.2 (C-4), 131.9 (C-9), 140.9 (C-5), 154.0 (C-1’), 176.6 (C-1); FT-IR 
(ATR):  = 3445 (w), 2645 (m), 2928 (m), 2878 (w), 1778 (vs), 1696 (s), 1485 (w), 1455 (m), 
1382 (vs), 1300 (m), 1256 (s), 1225 (s), 1202 (vs), 1142 (m), 1120 (m), 1104 (m), 1076 (m), 1055 
(m), 988 (s), 954 (m), 901 (w), 846 (w), 818 (w), 775 (w), 760 (w), 733,6 (w), 707 (m), 638 (w), 
527 (w), 461 (w) cm–1; HRMS (ESI) m/z: [M+Na]+ Calcd for C19H31NO4Na 360.2145; Found 
360.2153. 
(4S)-3-[(4Z)-3-Hydroxy-2,5,9-trimethyldeca-4,8-dienoyl)-4-isopropyl-1,3-oxazolidin-2-one 
[(Z)-14a]. Chromatography (PE/EtOAc 2 : 1) afforded (4'Z)-14a (25.2 mg, 0.07 mmol, 7%, purity 
80% 1H NMR, Rf = 0.35), (2'R,3'S,4'Z)-14a (201 mg, 0.59 mmol, 59%, purity 95% 1H NMR, Rf = 
0.31) and (3'S,4'Z)-14a (56 mg, 0.17 mmol, 17%, purity 95% 1H NMR, Rf = 0.20) as colorless oils. 
(2'R,3'S,4'Z)-14a: 20D]α[ = +26.7 (c = 1.2 in CH2Cl2); 1H NMR (400 MHz, CDCl3) δ (ppm) = 0.87 
(d, J = 6.9 Hz, 3H, 5’-H or 6’-H), 0.91 (d, J = 6.9 Hz, 3H, 5’-H or 6’-H), 1.12 (d, J = 7.0 Hz, 3H, 
13-H), 1.60 (s, 3H, 10-H or 11-H), 1.67 (s, 3H, 10-H or 11-H), 1.74 (s, 3H, 12-H), 1.98-2.22 (m, 
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4H, 6-H, 7-H), 2.26-2.42 (m, 1H, 4’-H), 3.77-3.88 (m, 1H, 2-H), 4.15-4.31 (m, 2H, 2’-H, 3’-Ha), 
4.44-4.56 (m, 2H, 3-H, 3’-Hb), 5.05-5.15 (m, 1H, 8-H), 5.18 (d, J = 9.3 Hz, 1H, 4-H); 13C{1H} 
NMR (100 MHz, CDCl3) δ (ppm) = 15.0 (C-13, C-6’), 17.8 (C-5’), 18.0 (C-12), 23.5 (C-10, C-
11), 25.7 (C-10), 26.7 (C-7), 28.7 (C-4’), 32.5 (C-6), 44.3 (C-2), 58.6 (C-3), 63.6 (C-3’), 70.3 (C-
2’), 123.9 (C-8), 126.1 (C-4), 132.4 (C-9), 141.4 (C-5), 154.0 (C-1’), 176.6 (C-1); FT-IR 
(ATR):  = 3497 (w), 2965 (m), 2926 (m), 2877 (m), 1774 (vs), 1696 (s), 1487 (w), 1454 (m), 
1374 (vs), 1300 (m), 1201 (vs), 1142 (m), 1119 (m), 1100 (m), 1054 (m), 1014 (m), 989 (s), 965 
(m), 954 (m), 904 (w), 845 (w), 819 (w), 775 (w), 761 (w), 709 (m), 640 (w), 555 (w), 533 (w), 
451 (w) cm–1; HRMS (ESI) m/z: [M+Na]+ Calcd for C19H31NO4Na 360.2145; Found 360.2159. 
(3'S,4'Z)-14a: 20D]α[ = +24.6 (c = 1.1 in CH2Cl2); 1H NMR (400 MHz, CDCl3) δ (ppm) = 0.87 (d, J 
= 6.9 Hz, 3H, 5’-H or 6’-H), 0.91 (d, J = 7.0 Hz, 3H, 5’-H or 6’-H), 1.12 (d, J = 7.0 Hz, 3H, 13-
H), 1.60 (s, 3H, 10-H or 11-H), 1.67 (s, 3H, 10-H or 11-H), 1.74 (s, 3H, 12-H), 1.98-2.22 (m, 4H, 
6-H, 7-H), 2.26-2.42 (m, 1H, 4’-H), 3.77-3.88 (m, 1H, 2’-H), 4.15-4.31 (m, 2H, 2’-H, 3’-Ha), 4.44-
4.56 (m, 2H, 3-H, 3’-Hb), 5.05-5.15 (m, 1H, 8-H), 5.18 (d, J = 9.3 Hz, 1H, 4-H); 13C{1H} NMR 
(100 MHz, CDCl3) δ (ppm) = 15.0 (C-13, C-6’), 17.8 (C-5’), 18.0 (C-12), 23.5 (C-10, C-11), 25.7 
(C-10), 26.7 (C-7), 28.7 (C-4’), 32.5 (C-6), 44.3 (C-2), 58.6 (C-3), 63.6 (C-3’), 70.3 (C-2’), 123.9 
(C-8), 126.1 (C-4), 132.4 (C-9), 141.4 (C-5), 154.0 (C-1’), 176.6 (C-1); FT-IR (ATR):  = 3469 
(w), 2964 (m), 2931 (m), 2977 (w), 1777 (s), 1696 (s), 1455 (m), 1382 (s), 1300 (m), 1255 (m), 
1225 (s), 1202 (s), 1143 (w), 1120 (m), 1101 (m), 1055 (m), 988 (s), 954 (m), 901 (w), 848 (w), 
819 (w), 775 (w), 707 (m), 638 (w), 595 (w), 528 (w), 449 (w) cm–1; HRMS (ESI) m/z: [M+Na]+ 
Calcd for C19H31NO4Na 360.2145; Found 360.2161. (4'Z)-14a: 20D]α[ = +30.2 (c = 1.2 in CH2Cl2); 
1H NMR (400 MHz, CDCl3) δ (ppm) =0.88 (d, J = 7.0 Hz, 3H, 5’-H or 6’-H), 0.90 (d, J = 7.1 Hz, 
3H, 5’-H or 6’-H), 1.06 (d, J = 6.9 Hz, 3H, 13-H), 1.58 (s, 3H, 10-H or 11-H), 1.66 (s, 3H, 10-H 
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or 11-H), 1.73 (s, 3H, 12-H), 2.03-2.19 (m, 4H, 6-H, 7-H), 2.30-2.46 (m, 1H, 4’-H), 3.82-3.95 (m, 
1H, 2-H), 4.15-4.34 (m, 3H, 2’-H, 3’-Ha), 4.36-4.51 (m, 2H, 3-H, 3’-Hb), 5.00-5.14 (m, 1H, 8-H), 
5.18 (d, J = 9.2 Hz, 1H, 4-H); 13C{1H} NMR (100 MHz, CDCl3) δ (ppm) = 14.4 (C-13), 14.6 (C-
6’), 17.9 (C-5’), 18.2 (C-12), 23.4 (C-10, C-11), 25.7 (C-10), 26.6 (C-7), 28.0 (C-4’), 38.6 (C-6), 
44.9 (C-2), 59.9 (C-3), 63.3 (C-3’), 71.3 (C-2’), 123.9 (C-8), 126.6 (C-4), 132.3 (C-9), 141.2 (C-
5), 154.3 (C-1’), 176.7 (C-1); FT-IR (ATR):  = 3517 (w), 2965 (m), 2931 (m), 2877 (w), 1776 
(vs), 1700 (s), 1487 (w), 1450 (w), 1386 (s), 1373 (s), 1301 (w), 1248 (m), 1205 (s), 1143 (w), 
1121 (m), 1056 (m), 1015 (m), 990 (m), 953 (w), 900 (w), 816 (w), 773 (w), 757 (w), 698 (w), 
634 (w), 533 (w) cm–1; HRMS (ESI) m/z: [M+Na]+ Calcd for C19H31NO4Na 360.2145; Found 
360.2148. 
(4S)-3-[(4E)-3-Hydroxy-5-phenylpent-4-enoyl]-4-isopropyl-1,3-oxazolidin-2-one (13b). Chro-
matography (PE/EtOAc 3 : 1) afforded 13b (93 mg, 307 μmol, 51%) as a colorless solid. Rf = 0.30. 
Analytical HPLC (Kromasil, flow 0.8 mL min–1, hexane/isopropanol 90 : 10): tR1 = 12.741 min 
(minor, 4%), tR2 = 15.086 min (major, syn,syn 13b, 96%). 20D]α[ = + 79.1 (c = 1.1 in CHCl3); 1H 
NMR (400 MHz, CDCl3) δ (ppm) = 0.89 (d, J = 6.9 Hz, 3H, 5’-H or 6’-H), 0.93 (d, J = 6.9 Hz, 
3H, 5’-H or 6’-H), 2.34–2.43 (m, 1H, 4’-H), 3.01 (s, 1H, OH), 3.22 (dd, J = 17.1 Hz, 8.6 Hz, 1H, 
2-Ha), 3.35 (dd, J = 17.1 Hz, 3.4 Hz, 1H, 2-Hb), 4.23 (dd, J = 9.2 Hz, 3.1 Hz, 1H, 3-Ha), 4.28 (dd, 
J = 9.2 Hz, 8.1 Hz, 1H, 3’-Hb), 4.46 (dt, J = 8.1 Hz, 3.4 Hz, 1H, 2’-H), 4.79–4.87 (m, 1H, 3-H), 
6.28 (dd, J = 16.0 Hz, 6.0 Hz, 1H, 4-H), 6.68 (dd, J = 16.0, 1.4 Hz, 1H, 5-H), 7.20–7.28 (m, 1H, 
p-H), 7.27–7.35 (m, 2H, m-H), 7.35–7.41 (m, 2H, o-H); 13C{1H} NMR (101 MHz, 
CDCl3) δ (ppm) = 14.7 (C-6’), 18.0 (C-5’), 28.5 (C-4’), 42.6 (C-2), 58.5 (C-2’), 63.6 (C-3’), 68.8 
(C-3), 126.6 (C-m), 127.8 (C-o), 128.6 (C-p), 130.0 (C-4), 130.8 (C-5), 136.5 (C-i), 154.1 (C-1’), 
171.9 (C-1); FT-IR (ATR):  = 3465 (w), 3026 (vw), 2963 (w), 2876 (w), 1774 (s), 1696 (s), 1487 
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(w), 1465 (w), 1449 (w), 1386 (s), 1373 (s), 1301 (m), 1204 (s), 1143 (w), 1119 (m), 1058 (m), 
1020 (m), 970 (m), 914 (w), 750 (m), 715 (w), 695 (m), 640 (w), 587 (vw), 543.38 (w), 472 (w) 
cm–1; HRMS (ESI) m/z: [M+Na]+ Calcd for C17H21NO4Na 326.1363; Found: 326.1344. 
(4S)-3-[(4E)-3-Hydroxy-5-(4-methoxyphenyl)pent-4-enoyl]-4-isopropyl-1,2-oxazolidin-2-one 
(13c). Chromatography (PE/EtOAc 2 : 1) afforded 13c (64 mg, 192 μmol, 30%) as a pale yellow 
oil. Rf = 0.21. Analytical HPLC (Kromasil, flow 0.8 mL min–1, hexane/isopropanol 95 : 5): 
tR1 = 35.312 min (minor, 2%), tR2 = 39.530 min (major, syn,syn 13c, 98%). 20D]α[ = + 50.5 (c = 1.0 
in CHCl3); 1H NMR (500 MHz, CDCl3) δ (ppm) = 0.89 (d, J = 6.9 Hz, 3H, 5’-H or 6’-H), 0.93 (d, 
J = 6.9 Hz, 3H, 5’-H or 6’-H), 2.35–2.44 (m, 1H, 4’-H), 2.93 (d, J = 4.5 Hz, 1H, OH), 3.22 (dd, 
J = 17.1 Hz, 8.7 Hz, 1H, 2-Ha), 3.34 (dd, J = 17.1 Hz, 3.3 Hz, 1H, 2-Hb), 3.81 (s, 3H, OMe), 4.23 
(dd, J = 9.1 Hz, 3.0 Hz, 1H, 3’-Ha), 4.29 (dd, J = 9.1 Hz, 8.2 Hz, 1H, 3’-Hb), 4.44–4.49 (m, 1H, 
2’-H), 4.76–4.84 (m, 1H, 3-H), 6.14 (dd, J = 15.9 Hz, 6.2 Hz, 1H, 4-H), 6.59–6.64 (m, 1H, 5-H), 
6.83–6.87 (m, 2H, m-H), 7.29–7.34 (m, 2H, o-H); 13C{1H} NMR (126 MHz, CDCl3) δ (ppm) = 
14.7 (C-6’), 18.0 (C-5’), 28.5 (C-4’), 42.7 (C-2), 55.3 (OMe), 58.5 (C-2’), 63.6 (C-3’), 69.0 (C-3), 
114.0 (C-m), 127.7 (C-4), 127.8 (C-o), 129.2 (C-i), 130.4 (C-5), 154.1 (C-1’), 159.4 (C-p), 172.0 
(C-1); FT-IR (ATR):  = 3490 (w), 2961 (m), 2930 (m), 2837 (w), 1778 (vs), 1698 (s), 1607 (s), 
1578 (w), 1511 (vs), 1464 (w), 1387 (s), 1301 (m), 1249 (vs), 1207 (s), 1176 (s), 1143 (w), 1108 
(m), 1032 (s), 971 (m), 816 (w), 775 (w), 714 (w), 641 (w), 538 (w) cm–1; HRMS (ESI) m/z: 
[M+Na]+ Calcd for C18H23NO5Na 356.1468; Found 356.1470. 
(4S)-3-[(4E)-3-Hydroxy-5-(4-methylphenyl)pent-4-enoyl]-4-isopropyl-1,2-oxazolidin-2-one 
(13d). Chromatography (PE/EtOAc 2.5 : 1) afforded 13d (36 mg, 113 μmol, 22%) as a pale yellow 
oil. Rf = 0.18. Analytical HPLC (OJ-H, flow 2.0 mL min–1, hexane/isopropanol 85 : 15): 
tR1 = 12.593 min (minor, 1%), tR2 = 16.199 min (major, syn,syn 13d, 99%). 20D]α[ = + 57.1 (c = 1.0 
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in CHCl3); 1H NMR (500 MHz, CDCl3) δ (ppm) = 0.89 (d, J = 7.0 Hz, 3H, 5’-H or 6’-H), 0.93 (d, 
J = 7.0 Hz, 3H, 5’-H or 6’-H), 2.30–2.43 (m, 4H, 4-H, CH3), 2.96 (s, 1H, OH), 3.22 (dd, 
J = 17.2 Hz, 8.7 Hz, 1H, 2-Ha), 3.34 (dd, J = 17.2 Hz, 3.3 Hz, 1H, 2-Hb), 4.23 (dd, J = 9.0 Hz, 
3.1 Hz, 1H, 3’-Ha), 4.29 (t, J = 9.0 Hz, 1H, 3’-Hb), 4.44–4.49 (m, 1H, 2’-H), 4.79–4.86 (m, 1H, 
3-H), 6.22 (dd, J = 15.9 Hz, 6.1 Hz, 1H, 4-H), 6.64 (d, J = 15.9 Hz, 1H, 5-H), 7.09–7.15 (m, 2H, 
m-H), 7.27–7.31 (m, 2H, o-H); 13C{1H} NMR (126 MHz, CDCl3) δ (ppm) = 14.7 (C-6’), 18.0 (C-
5’), 21.2 (CH3), 28.5 (C-4’), 42.6 (C-2), 58.5 (C-2’), 63.6 (C-3’), 68.9 (C-3), 126.5 (C-o), 128.8 
(C-4), 129.3 (C-m), 130.7 (C-5), 133.6 (C-i), 137.7 (C-p), 154.0 (C-1’), 175.0 (C-1); FT-IR 
(ATR):  = 3445 (w), 2961 (m), 2923 (m), 1779 (vs), 1698 (s), 1514 (m), 1485 (w), 1464 (w), 
1386 (vs), 1302 (m), 1206 (s), 1143 (w), 1106 (m), 1059 (m), 1020 (m), 971 (m), 802 (m), 775 
(w), 715 (w), 641 (w), 529 (w), 464 (w) cm–1; HRMS (ESI) m/z: [M+Na]+ Calcd for C18H23NO4Na 
340.1519; Found 340.1529. 
(4S)-3-[(4E)-5-(4-Chlorophenyl)-3-hydroxypent-4-enoyl)-4-isopropyl-1,3-oxazolidin-2-one 
(13e). Chromatography (PE/EtOAc 3 : 1) afforded 13e (70 mg, 207 μmol, 33%) as a pale yellow 
oil. Rf = 0.20. Analytical HPLC (OJ-H, flow 1.0 mL min–1, hexane/isopropanol 85 : 15): 
tR1 = 24.473 min (minor, 6%), tR2 = 28.815 min (major, syn,syn 13e, 94%). 20D]α[ = + 53.3 (c = 1.0 
in CHCl3); 1H NMR (500 MHz, CDCl3) δ (ppm) = 0.89 (d, J = 6.9 Hz, 3H, 5’-H or 6’-H), 0.94 (d, 
J = 6.9 Hz, 3H, 5’-H or 6’-H), 2.34–2.43 (m, 1H, 4’-H), 3.05 (s, 1H, OH), 3.19 (dd, J = 17.2 Hz, 
8.8 Hz, 1H, 2-Ha), 3.36 (dd, J = 17.2 Hz, 3.2 Hz, 1H, 2-Hb), 4.24 (dd, J = 9.2 Hz, 3.2 Hz, 1H, 
3’-Ha), 4.27–4.32 (m, 1H, 3’-Hb), 4.44–4.49 (m, 1H, 2’-H), 4.79–4.85 (m, 1H, 3-H), 6.25 (dd, 
J = 15.9 Hz, 5.9 Hz, 1H, 4-H), 6.64 (dd, J = 15.9 Hz, 1.5 Hz, 1H, 5-H), 7.27–7.33 (m, 4H, o-H, m-
H); 13C{1H} NMR (126 MHz, CDCl3) δ (ppm) = 14.7 (C-6’), 18.0 (C-5’), 28.5 (C-4’), 42.5 (C-2), 
58.5 (C-2’), 63.7 (C-3’), 68.6 (C-3), 127.8 (C-m), 128.8 (C-o), 129.5 (C-5), 130.5 (C-4), 133.4 
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(C-p), 135.0 (C-i), 154.0 (C-1’), 172.1 (C-1); FT-IR (ATR):  = 3468 (w), 2964 (m), 2162 (w), 
2026 (w), 1780 (vs), 1699 (s), 1492 (m), 1387 (s), 1302 (m), 1207 (s), 1092 (m), 1059 (w), 1014 
(m), 971 (m), 808 (w), 776 (w) cm–1; HRMS (ESI) m/z: [M+Na]+ Calcd for C17H20ClNO4Na 
360.0973; Found 360.0975. 
(4S)-3-[(4E)-3-Hydroxy-5-(4-nitrophenyl)pent-4-enoyl]-4-isopropyl-1,3-oxazolidin-2-one 
(13f). Chromatography (PE/EtOAc 2.5 : 1) afforded 13f (51 mg, 146 μmol, 24%) as an orange oil. 
Rf = 0.30; 20D]α[ = + 41.3 (c = 1.0 in CHCl3); 1H NMR (500 MHz, CDCl3) δ (ppm) = 0.90 (d, 
J = 7.0 Hz, 3H, 5’-H or 6’-H), 0.95 (d, J = 7.0 Hz, 3H, 5’-H or 6’-H), 2.31–2.44 (m, 1H, 4’-H), 
3.18 (dd, J = 17.4 Hz, 8.9 Hz, 1H, 2-Ha), 3.41 (dd, J = 17.4 Hz, 3.2 Hz, 1H, 2-Hb), 4.26 (dd, 
J = 9.2 Hz, 3.0 Hz, 1H, 3’-Ha), 4.31 (dd, J = 9.2 Hz, 8.2 Hz, 1H, 3’-Hb), 4.45–4.50 (m, 1H, 2’-H), 
4.82–4.93 (m, 1H, 3-H), 6.45 (dd, J = 16.0 Hz, 5.3 Hz, 1H, 4-H), 6.78 (dd, J = 16.0 Hz, 1.6 Hz, 
1H, 5-H), 7.49–7.53 (m, 2H, o-H), 8.17–8.21 (m, 2H, m-H); 13C{1H} NMR (126 MHz, CDCl3) 
δ (ppm) = 14.7 (C-6’), 18.0 (C-5’), 28.5 (C-4’), 42.4 (C-2), 58.5 (C-2’), 63.7 (C-3’), 68.2 (C-3), 
124.0 (C-m), 127.1 (C-o), 128.4 (C-5), 134.7 (C-4), 143.0 (C-i), 147.1 (C-p), 154.1 (C-1’), 171.8 
(C-1); FT-IR (ATR):  = 3428 (w), 2963 (m), 2928 (w), 2875 (w), 1777 (vs), 1698 (s), 1597 (m), 
1516 (s), 1487 (w), 1466 (w), 1387 (s), 1342 (vs), 1302 (w), 1207 (m), 1143 (w), 1109 (m), 1058 
(m), 1019 (m), 973 (m), 863 (w), 824 (w), 800 (w), 773 (m), 717 (w), 692 (w), 640 (w) cm–1; 
HRMS (ESI) m/z: [M+Na]+ Calcd for C17H20N2O6Na 371.1214; Found 371.1189. 
(S)-3-((2'R,3'S,E)- or (S)-3-((2'S,3'R,E)-3-Hydroxy-2-methyl-5-phenylpent-4-enoyl)-4-isopro-
pyloxazolidin-2-one (14b). Chromatography (PE/EtOAc 3 : 1) afforded 14b (185 mg, 582 μmol, 
92%) as a colorless solid. Rf = 0.27. Analytical HPLC (Kromasil, flow 0.8 mL min–1, hexane/ 
isopropanol 90 : 10): tR1 = 7.950 min (minor, 1%), tR2 = 8.565 min (minor, 2%), tR3 = 9.612 min 
(minor, syn,anti 5%), tR4 = 11.212 min (major, syn,syn 14b, 93%). The diastereomers could be 
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separated via preparative HPLC: syn,syn 14b (170 mg, 536 µmol, 85%) and anti,syn 14b (9.0 mg, 
28.4 µmol, 5%). syn,syn 14b: 20D]α[ = + 46.6 (c = 0.9 in CHCl3); 1H NMR (500 MHz, 
CDCl3) δ (ppm) = 0.83 (d, J = 6.9 Hz, 3H, 5’-H or 6’-H), 0.90 (d, J = 6.9 Hz, 3H, 5’-H or 6’-H), 
1.22 (d, J = 6.9 Hz, 3H, 6-H), 2.28–2.38 (m, 1H, 4’-H), 2.80 (d, J = 3.1 Hz, 1H, OH), 4.11 (qd, 
J = 6.9 Hz, 4.1 Hz, 1H, 2-H), 4.22 (dd, J = 9.2 Hz, 3.1 Hz, 1H, 3’-Ha), 4.29 (dd, J = 9.2 Hz, 8.2 Hz, 
1H, 3’-Hb), 4.47 (ddd, J = 8.2 Hz, 3.9 Hz, 3.1 Hz, 1H, 2’-H), 4.67 (dddd, J = 5.9 Hz, 4.1 Hz, 
3.1 Hz, 1.4 Hz, 1H, 3-H), 6.22 (dd, J = 15.9 Hz, 5.9 Hz, 1H, 4-H), 6.67 (dd, J = 15.9 Hz, 1.4 Hz, 
1H, 5-H), 7.21–7.27 (m, 1H, p-H), 7.31 (dd, J = 8.4 Hz, 6.8 Hz, 2H, m-H), 7.36–7.40 (m, 2H, o-
H); 13C{1H} NMR (126 MHz, CDCl3) δ (ppm) = 11.3 (C-6), 14.6 (C-6’), 17.9 (C-5’), 28.6 (C-4’), 
42.8 (C-2), 58.7 (C-2’), 63.4 (C-3’), 73.5 (C-3), 126.6 (C-m), 127.7 (C-o), 128.5 (C-4), 128.6 (C-
o), 131.7 (C-5), 136.6 (C-i), 154.1 (C-1’), 175.8 (C-1); FT-IR (ATR):  = 3476 (w), 2965 (w), 
2933 (w), 2877 (w), 1773 (vs), 1696 (s), 1488 (w), 1451 (w), 1385 (s), 1300 (m), 1203 (s), 1143 
(w), 1121 (m), 1055 (w), 1016 (w), 988 (w), 967 (m), 754 (m), 696 (m), 639 (w), 490 (w) cm–1; 
HRMS (ESI) m/z: [M+Na]+ Calcd for C18H23NO4Na 340.1519; Found 340.1519. anti,syn 14b: 1H 
NMR (500 MHz, CDCl3) δ (ppm) = 0.79 (d, J = 6.9 Hz, 3H, 5’-H or 6’-H), 0.89 (d, J = 6.9 Hz, 
3H, 5’-H or 6’-H), 1.24 (d, J = 6.9 Hz, 3H, 6-H), 2.35 (qd, J = 7.0 Hz, 3.9 Hz, 1H, 4’-H), 2.84 (d, 
J = 7.7 Hz, 1H, OH), 4.13 (qd, J = 7.1 Hz, J = 6.8 Hz, 1H, 2-H), 4.21 (dd, J = 9.1 Hz, 3.0 Hz, 1H, 
3’-Ha), 4.28 (dd, J = 9.1 Hz, 8.3 Hz, 1H, 3’-Hb), 4.39 (dd, J = 6.8 Hz, 6.5 Hz, 1H, 3-H), 4.46 (ddd, 
J = 8.2 Hz, 3.9 Hz, 3.0 Hz, 1H, 2’-H), 6.25 (dd, J = 15.9 Hz, 6.5 Hz, 1H, 4-H), 6.65 (dd, 
J = 15.9 Hz, 1.3 Hz, 1H, 5-H), 7.25 (d, J = 9.3 Hz, 1H, p-H), 7.29–7.34 (m, 2H, m-H), 7.35–7.40 
(m, 2H, o-H); 13C{1H} NMR (126 MHz, CDCl3) δ (ppm) = 14.5 (C-6), 14.6 (C-6’), 17.9 (C-5’), 
28.4 (C-4’), 43.0 (C-2), 58.8 (C-2’), 63.3 (C-3’), 75.8 (C-3), 126.6 (C-m), 127.9 (C-o), 128.6 (C-
o), 129.7 (C-4), 132.0 (C-5), 136.4 (C-i), 154.2 (C-1’), 176.3 (C-1); FT-IR (ATR):  = 3487 (w), 
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2964 (w), 2925 (w), 2876 (w), 1775 (vs), 1698 (s), 1599 (vw), 1492 (w), 1453 (w), 1383 (s), 1301 
(m), 1202 (s), 1143 (w), 1118 (m), 1052 (w), 1016 (m), 988 (m), 966 (m), 906 (w), 846 (w), 802 
(w), 749 (m), 694 (m), 635 (w), 555 (w), 459 (w) cm–1; HRMS (ESI) m/z: [M+Na]+ Calcd for 
C18H23NO4Na 340.1519; Found 340.1525. 
(4S)-3-[(4E)-3-Hydroxy-5-(4-methoxyphenyl)-2-methylpent-4-enoyl]-4-isopropyl-1,3-oxazoli-
din-2-one (14c). Chromatography (PE/EtOAc 3 : 1 → 2 : 1) afforded 14c (125 mg, 360 μmol, 
63%) as a pale yellow oil. Rf = 0.44 (2 : 1). Analytical HPLC (OJ-H, flow 1.5 mL min–1, hexane/ 
isopropanol 80 : 20): tR1 = 19.310 min (major, syn,syn 14c, 85%), tR2 = 22.686 min (minor, 15%). 
20
D]α[ = + 23.6 (c = 1.0 in CHCl3); 1H NMR (500 MHz, CDCl3) δ (ppm) = 0.82 (d, J = 6.9 Hz, 3H, 
5’-H or 6’-H), 0.90 (d, J = 6.9 Hz, 3H, 5’-H or 6’-H), 1.22 (d, J = 6.9 Hz, 3H, 6-H), 2.27–2.41 (m, 
1H, 4’-H), 2.71 (d, J = 3.0 Hz, 1H, OH), 3.81 (s, 3H, OMe), 4.05–4.16 (m, 2H, 2-H), 4.22 (dd, 
J = 9.1 Hz, 3.0 Hz, 1H, 3’-Ha), 4.26–4.31 (m, 1H, 3’-Hb), 4.42–4.50 (m, 1H, 2’-H), 4.60–4.68 (m, 
1H, 3-H), 6.08 (dd, J = 15.9 Hz, 6.2 Hz, 1H, 4-H), 6.58–6.63 (m, 1H, 5-H), 6.82–6.87 (m, 2H, m-
H), 7.29–7.34 (m, 2H, o-H); 13C{1H} NMR (126 MHz, CDCl3) δ (ppm) = 11.4 (C-6), 14.6 (C-6’), 
18.0 (C-5’), 28.5 (C-4’), 42.9 (C-2), 55.3 (OMe), 58.7 (C-2’), 63.4 (C-3’), 73.7 (C-3), 114.0 (C-
m), 126.3 (C-4), 127.8 (C-o), 129.3 (C-i), 131.3 (C-5), 154.1 (C-1’), 159.3 (C-p), 175.8 (C-1); FT-
IR (ATR):  = 3469 (w), 2964 (m), 2935 (w), 2878 (w), 2839 (w), 1775 (vs), 1698 (m), 1607 (m), 
1512 (s), 1464 (w), 1386 (s), 1301 (m), 1249 (s), 1205 (s), 1176 (m), 1120 (m), 1032 (m), 968 (m), 
824 (w), 709 (w) cm–1; HRMS (ESI) m/z: [M+Na]+ Calcd for C19H25NO5Na 370.1625; Found 
370.1594. 
(4S)-3-[(4E)-3-Hydroxy-2-methyl-5-(4-methylphenyl)pent-4-enoyl]-4-isopropyl-1,3-oxazoli-
din-2-one (14d). Chromatography (PE/EtOAc 2.5 : 1) afforded 14d (60 mg, 181 μmol, 30%) as a 
pale yellow oil. Rf = 0.36. Analytical HPLC (OD-H, flow 1.0 mL min–1, hexane/isopropanol 
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85 : 15): tR1 = 10.968 min (minor, 1%), tR2 = 14.111 min (minor, 6%), tR3 = 16.710 min (major, 
syn,syn 14d, 93%). 20D]α[ = + 24.9 (c = 1.0 in CHCl3); 1H NMR (500 MHz, CDCl3) δ (ppm) = 0.80 
(d, J = 7.0 Hz, 3H, 5’-H or 6’-H), 0.88 (d, J = 7.0 Hz, 3H, 5’-H or 6’-H), 1.21 (d, J = 7.0 Hz, 3H, 
6-H), 2.27–2.35 (m, 1H, 4’-H), 2.32 (s, 3H, CH3), 2.84–2.91 (m, 1H, OH), 4.05–4.13 (m, 1H, 2-
H), 4.19 (dd, J = 9.1 Hz, 3.0 Hz, 1H, 3’-Ha), 4.26 (dd, J = 9.1 Hz, 1H, 3’-Hb), 4.42–4.48 (m, 1H, 
2’-H), 4.62–4.67 (m, 1H, 3-H), 6.17 (dd, J = 15.9 Hz, 6.2 Hz, 1H, 4-H), 6.62 (dd, J = 15.9 Hz, 
1.4 Hz, 1H, 5-H), 7.08–7.13 (m, 2H, m-H), 7.24–7.30 (m, 2H, o-H); 13C{1H} 
NMR (126 MHz, CDCl3) δ (ppm) = 11.4 (C-6), 14.6 (C-6’), 17.9 (C-5’), 21.2 (CH3), 28.5 (C-4’), 
42.9 (C-2), 58.6 (C-2’), 63.4 (C-3’), 73.6 (C-3), 126.5 (C-o), 127.6 (C-4), 129.2 (C-m), 131.6 (C-
5), 133.8 (C-i), 137.5 (C-p), 154.2 (C-1’), 175.7 (C-1); FT-IR (ATR):  = 3480 (w), 2965 (m), 
2924 (m), 2876 (m), 1771 (vs), 1695 (s), 1514 (m), 1486 (w), 1456 (m), 1373 (s), 1300 (m), 1201 
(vs), 1119 (m), 1054 (m), 1016 (m), 966 (s), 909 (m), 802 (m), 775 (m), 730 (vs), 710 (s), 647 (w), 
510 (w), 476 (w), 433 (w) cm–1; HRMS (ESI) m/z: [M+Na]+ Calcd for C19H25NO4Na 354.1676; 
Found 354.1672. 
(4S)-3-[(4E)-5-(4-Chlorophenyl)-3-hydroxy-2-methylpent-4-enoyl]-4-isopropyl-1,3-oxazoli-
din-2-one (14e). Chromatography (PE/EtOAc 3 : 1) afforded 14e (74 mg, 210 μmol, 34%) as a 
colorless oil. Rf = 0.26. Analytical HPLC (Kromasil, flow 0.8 mL min–1, hexane/isopropanol 
95 : 5): tR1 = 9.076 min (minor, 2%), tR2 = 11.987 min (minor, 3%), tR3 = 14.852 min (minor, 9%), 
tR4 = 18.948 min (major, syn,syn 14e, 86%). 20D]α[ = + 24.4 (c = 1.0 in CHCl3); 1H NMR (500 MHz, 
CDCl3) δ (ppm) = 0.84 (d, J = 6.9 Hz, 3H, 5’-H or 6’-H), 0.91 (d, J = 6.9 Hz, 3H, 5’-H or 6’-H), 
1.21 (d, J = 6.9 Hz, 3H, 6-H), 2.30–3.39 (m, 1H, 4’-H), 2.86 (d, J = 3.0 Hz, 1H, OH), 4.07–4.15 
(m, 1H, 2-H), 4.23 (dd, J = 9.2 Hz, 3.0 Hz, 1H, 3’-Ha), 4.27–4.32 (m, 1H, 3’-Hb), 4.45–4.49 (m, 
1H, 2’-H), 4.65–4.70 (m, 1H, 3-H), 6.19 (dd, J = 15.9 Hz, 5.8 Hz, 1H, 4-H), 6.63 (dd, J = 15.9 Hz, 
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1.5 Hz, 1H, 5-H), 7.27–7.34 (m, 4H, o-H, m-H); 13C{1H} NMR (126 MHz, CDCl3) δ (ppm) = 11.3 
(C-6), 14.7 (C-6’), 18.0 (C-5’), 28.6 (C-4’), 42.7 (C-2), 58.7 (C-2’), 63.4 (C-3’), 73.3 (C-3), 127.8 
(C-m), 128.7 (C-o), 129.2 (C-4), 130.4 (C-5), 133.4 (C-p), 135.1 (C-i), 154.2 (C-1’), 175.8 (C-1); 
FT-IR (ATR):  = 3491 (w), 2964 (m), 2935 (w), 2876 (w), 2208 (s), 1776 (vs), 1698 (m), 1656 
(w), 1602 (w), 1510 (w), 1491 (w), 1462 (w), 1386 (s), 1299 (m), 1254 (m), 1206 (s), 1173 (w), 
1120 (w), 1091 (w), 1033 (m), 968 (w), 837 (w), 756 (w), 702 (w) cm–1; HRMS (ESI) m/z: 
[M+Na]+ Calcd for C18H22ClNO4Na 374.1130; Found 374.1111. 
(4S)-3-[(4E)-3-Hydroxy-2-methyl-5-(4-nitrophenyl)pent-4-enoyl]-4-isopropyl-1,3-oxazolidin-
2-one (14f). Chromatography (PE/EtOAc 3 : 1) afforded 14f (92 mg, 254 μmol, 52%) as an orange 
oil. Rf = 0.26. Analytical HPLC (Kromasil, flow 0.8 mL min–1, hexane/isopropanol 95 : 5): 
tR1 = 21.884 min (minor, 4%), tR2 = 25.025 min (minor, 2%), tR3 = 27.798 min (major, syn 14f, 
94%). 20D]α[ = + 27.8 (c = 1.0 in CHCl3); 1H NMR (500 MHz, CDCl3) δ (ppm) = 0.87 (d, 
J = 7.0 Hz, 3H, 5’-H or 6’-H), 0.93 (d, J = 7.0 Hz, 3H, 5’-H or 6’-H), 1.21 (d, J = 7.0 Hz, 3H, 6-
H), 2.30–2.43 (m, 1H, 4’-H), 3.08 (s, 1H, OH), 4.08–4.16 (m, 1H, 2-H), 4.25 (dd, J = 9.1 Hz, 
2.9 Hz, 1H, 3’-Ha), 4.29–4.35 (m, 1H, 3’-Hb), 4.45–4.51 (m, 1H, 2’-H), 4.72–4.78 (m, 1H, 3-H), 
6.40 (dd, J = 15.9 Hz, 5.3 Hz, 1H, 4-H), 6.78 (dd, J = 16.0 Hz, 1.6 Hz, 1H, 5-H), 7.45–7.58 (m, 
2H, o-H), 8.16–8.22 (m, 2H, m-H); 13C{1H} NMR (126 MHz, CDCl3) δ (ppm) = 11.1 (C-6), 14.7 
(C-6’), 18.0 (C-5’), 28.6 (C-4’), 42.4 (C-2), 58.8 (C-2’), 63.6 (C-3’), 72.8 (C-3), 124.0 (C-m), 
127.1 (C-o), 129.3 (C-4), 133.4 (C-5), 143.1 (C-i), 147.0 (C-p), 154.2 (C-1’), 175.7 (C-1); FT-IR 
(ATR):  = 3483 (w), 2965 (m), 2877 (w), 1774 (s), 1699 (s), 1596 (m), 1516 (s), 1488 (w), 1462 
(w), 1387 (m), 1343 (vs), 1301 (w), 1206 (m), 1110 (m), 1054 (w), 1016, (w), 972 (w), 860 (w), 
824 (w), 750 (w), 709 (w) cm–1; HRMS (ESI) m/z: [M+Na]+ Calcd for C18H22N2O6Na 385.1370; 
Found 385.1344. 
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(4S)-3-[(4E)-3-hydroxyhex-4-enoyl]-4-isopropyl-1,3-oxazolidin-2-one (13g). Chromatography 
(SiO2, PE/EtOAc 3 : 1) afforded 13g (42 mg, 157 μmol, 54%) as a colorless oil. Rf = 0.22. 
Analytical HPLC (OJ-H, flow 1.0 mL min–1, hexane/isopropanol 90 : 10): tR1 = 10.877 min 
(minor, 10%), tR2 = 16.710 min (major, syn,syn 13g, 90%). 20D]α[ = + 96.0 (c = 1.0 in CHCl3); 1H 
NMR (400 MHz, CDCl3) δ (ppm) = 0.89 (d, J = 6.9 Hz, 3H, 5’-H or 6’-H), 0.93 (d, J = 6.9 Hz, 
3H, 5’-H or 6’-H), 1.71 (dt, J = 6.4 Hz, 1.3 Hz, 3H, 6-H), 2.31–2.38 (m, 1H, 4’-H), 2.79 (s, 1H, 
OH), 3.04–3.14 (m, 1H, 2-Ha), 3.23 (dd, J = 17.1 Hz, 3.3 Hz, 1H, 2-Hb), 4.22 (dd, J = 9.2 Hz, 
3.0 Hz, 1H, 3’-Ha), 4.29 (dd, J = 9.2 Hz, 8.1 Hz, 1H, 3’-Hb), 4.45 (dt, J = 8.1 Hz, 3.0 Hz, 1H, 2’-
H), 4.53-4.62 (m, 1H, 3-H), 5.56 (ddq, J = 15.3 Hz, 6.6 Hz, 1.6 Hz, 1H, 4-H), 5.70–5.83 (m, 1H, 
5-H); 13C{1H} NMR (100 MHz, CDCl3) δ (ppm) = 14.9 (C-6'), 17.8 (C-5’), 18.1 (C-6), 28.6 (C-
4’), 42.8 (C-2), 58.6 (C-2’), 63.7 (C-3’), 68.9 (C-3), 127.6 (C-5), 131.9 (C-4), 154.3 (C-1), 172.3 
(C-1'); FT-IR (ATR):  = 3504 (w), 2964 (w), 2922 (w), 2877 (w), 2163 (w), 1990 (w), 1775 (vs), 
1697 (s), 1486 (w), 1387 (s), 1373 (s), 1302 (m), 1204 (s), 1143 (m), 1120 (m), 1103 (m), 1058 
(m), 1021 (m), 969 (m), 929 (w), 876 (w), 775 (w), 713 (w), 641 (w), 523 (w) cm–1; HRMS (ESI) 
m/z: [M+Na]+ Calcd for C12H19NO4Na 264.1206; Found 264.1195. 
(4S)-3-(3-(Cyclopent-1-en-1-yl)-3-hydroxypropanoyl)-4-isopropyl-1,3-oxazolidin-2-one (13h). 
Chromatography (SiO2, PE/EtOAc 3 : 1) afforded 13h (89 mg, 333 μmol, 56%) as a colorless oil. 
Rf = 0.19. Analytical HPLC (Kromasil, flow 0.5 mL min–1, hexane/isopropanol 90 : 10): 
tR1 = 20.094 min (41%), tR2 = 21.978 min (59%). 20D]α[ = + 102.0 (c = 1.0 in CHCl3); 1H NMR 
(500 MHz, CDCl3) δ (ppm) = 0.89 (d, J = 7.0 Hz, 3H, 5’-H or. 6’-H), 0.93 (d, J = 7.0 Hz, 3H, 5’-
H or 6’-H), 1.85–1.97 (m, 2H, 7-H), 2.30–2.43 (m, 5H, 4’-H, 6-H, 8-H), 2.84 (s, 1H, OH), 3.18 
(dd, J = 17.1 Hz, 9.3 Hz, 1H, 2-Ha), 3.27 (dd, J = 17.1 Hz, 3.1 Hz, 1H, 2-Hb), 4.23 (dd, J = 9.1 Hz, 
3.0 Hz, 1H, 3’-Ha), 4.29 (dd, J = 9.1 Hz, 8.3 Hz, 1H, 3’-Hb), 4.44–4.49 (m, 1H, 2’-H), 4.75 (d, 
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J = 9.3 Hz, 1H, 3-H), 5.65–5.73 (m, 1H, 5-H); 13C{1H} NMR (126 MHz, CDCl3) δ (ppm) = 14.7 
(C-6’), 18.0 (C-5’), 23.3 (C-7), 28.05 (C-4’), 31.8 (C-6), 32.3 (C-8), 41.5 (C-2), 58.5 (C-2’), 63.6 
(C-3’), 67.4 (C-3), 126.0 (C-5), 144.9 (C-4), 154.1 (C-1’), 172.4 (C-1); FT-IR (ATR):  = 3531 
(w), 2962 (m), 2876 (w), 1779 (vs), 1702 (vs), 1487 (w), 1467 (w), 1375 (s), 1342 (w), 1304 (s), 
1207 (s), 1151 (m), 1118 (m), 1063 (m), 1040 (m), 1017 (m), 984 (w), 969 (m), 825 (w), 774 (m), 
731 (w), 642 (w), 621 (m), 594 (w), 528 (w) cm–1; HRMS (ESI) m/z: [M+Na]+ Calcd for 
C14H21NO4 290.1363; Found 290.1349. 
(4S)-3-[(4E)-3-Hydroxy-2-methylhex-4-enoyl]-4-isopropyl-1,3-oxazolidin-2-one (14g). Chro-
matography (SiO2, PE/EtOAc 3 : 1) afforded 14g (137 mg, 537 μmol, 90%) as a colorless oil. 
Rf = 0.25. Analytical HPLC (OJ-H, flow 0.5 mL min–1, hexane/isopropanol 85 : 15): tR1 = 
12.997 min (major, syn,syn 14g, 85%), tR2 = 15.642 min (minor, 12%), tR3 = 17.602 min (minor, 
3%). 20D]α[ = + 73.3 (c = 0.9 in CHCl3); 1H NMR (400 MHz, CDCl3) δ (ppm) = 0.90 (d, J = 6.9 Hz, 
3H, 5’-H or 6’-H), 0.92 (d, J = 6.9 Hz, 3H, 5’-H or 6’-H), 1.16 (d, J = 6.9 Hz, 3H, 7-H), 1.68–1.74 
(m, 3H, 6-H), 2.30–2.39 (m, 1H, 4’-H), 2.56 (s, 1H, OH), 3.99 (qd, J = 6.9  Hz, 4.5 Hz, 1H, 2-H), 
4.22 (dd, J = 9.2 Hz, 3.0 Hz, 1H, 3’-Ha), 4.25-4.32 (m, 1H, 3’-Hb), 4.37–4.43 (m, 1H, 2’-H), 4.43–
4.50 (m, 1H, 3-H), 5.46–5.55 (m, 1H, 4-H), 5.70–5.82 (m, 1H, 5-H); 13C{1H} NMR (101 MHz, 
CDCl3) δ (ppm) = 11.4 (C-7), 14.7 (C-6’), 17.8 (C-5’), 17.9 (C-6), 28.6 (C-4’), 42.7 (C-2), 58.6 
(C-2’), 63.4 (C-3’), 73.8 (C-3), 128.6 (C-5), 130.2 (C-4), 154.2 (C-1), 175.8 (C-1’); FT-IR (ATR): 
 = 3499 (w), 2965 (w), 2937 (w), 2878 (w), 1770 (vs), 1694 (s), 1487 (w), 1454 (w), 1372 (s), 
1300 (m), 1200 (s), 1142 (m), 1120 (m), 1101 (m), 1055 (w), 11051 (m), 989 (m), 965 (s), 926 
(w), 860 (w), 818 (w), 775 (w), 708 (s), 638 (w), 534 (w), 460 (w) cm–1; HRMS (ESI) m/z: 
[M+Na]+ Calcd for C13H21NO4Na 278.1363; Found 278.1335. 
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(4S)-3-(3-Cyclopent-1-en-1-yl-3-hydroxy-2-methylpropanoyl)-4-isopropyl-1,3-oxazolidin-2-
one (14h). Chromatography (SiO2, PE/EtOAc 3 : 1) afforded 14h (132 mg, 469 μmol, 78%) as a 
colorless oil. Rf = 0.35. Analytical HPLC (Kromasil, flow 0.8 mL min–1, hexane/isopropanol 
90 : 10): tR1 = 8.604 min (minor, 7%), tR2 = 9.774 min (35%), tR3 = 10.871 min (52%), tR4 = 
11.529 min (6%). 20D]α[ = + 58.2 (c = 1.0 in CHCl3); 1H NMR (500 MHz, CDCl3) δ (ppm) = 0.89 
(d, J = 7.0 Hz, 3H, 5’-H or 6’-H), 0.92 (d, J = 7.0 Hz, 3H, 5’-H or 6’-H), 1.12 (d, J = 7.0 Hz, 3H, 
9-H), 1.86–1.93 (m, 2H, 7-H), 2.26–2.41 (m, 5H, 4-H, 6-H, 8-H), 2.47 (s, 1H, OH), 4.05 (qd, 
J = 7.0 Hz, 3.8 Hz, 1H, 2-H), 4.22 (dd, J = 9.1 Hz, 3.2 Hz, 1H, 3’-Ha), 4.26–4.31 (m, 3’-Hb), 4.42–
4.51 (m, 1H, 2’-H), 4.62–4.67 (m, 1H, 3-H), 5.68–5.74 (m, 1H, 5-H); 13C{1H} NMR (126 MHz, 
CDCl3) δ (ppm) = 10.3 (C-9), 14.7 (C-6’), 17.9 (C-5’), 23.4 (C-7), 28.5 (C-4’), 32.3 (C-6), 32.4 
(C-8), 41.1 (C-2), 58.5 (C-2’), 63.3 (C-3’), 71.8 (C-3), 126.4 (C-5), 144.2 (C-4), 153.8 (C-1’), 
176.3 (C-1); FT-IR (ATR):  = 3500 (w), 2963 (m), 2849 (w), 1776 (vs), 1700 (s), 1487 (w), 1459 
(w), 1386 (s), 1301 (m), 1204 (vs), 1145 (w), 1120 (m), 1102 (m), 1055 (m), 1015 (m), 989 (m), 
953 (w), 774 (w), 697 (w) cm–1; HRMS (ESI) m/z: [M+Na]+ Calcd for C15H23NO4Na 304.1519; 
Found 304.1510. 
(4S)-3-[(2S,3S,4E)-3-hydroxy-2-(1-hydroxy-1-methylethyl)-5-phenylpent-4-enoyl]-4-isopropyl-
1,3-oxazolidin-2-one (21). Chromatography on SiO2 with PE/EtOAc (10 : 1 → 1 : 1) gave 21 (93.0 
mg, 0.27 mmol, 27%) as a yellowish oil. Rf = 0.11 (PE/EtOAc 4 : 1). 1H NMR (400 MHz, CDCl3) 
δ (ppm) = 0.49 (d, J = 7.0 Hz, 3H, 1-H), 0.79 (d, J = 7.0 Hz, 3H, 2-H), 1.32 (s, 3H, 11-H), 1.46 (s, 
3H, 10-H), 2.12–2.25 (m, 1H, 3-H), 4.13 (dd, J = 2.7 Hz, 9.2 Hz, 1H, 5-Ha), 4.21 (dd, J = 8.5 Hz, 
9.2 Hz, 1H, 5-Hb), 4.42 (d, J = 3.6 Hz, 1H, 8-H), 4.48–4.53 (m, 1H, 4-H), 4.95–5.02 (m, 1H, 12-
H), 6.30 (dd, J = 4.4 Hz, 16.0 Hz, 1H, 13-H), 6.70 (dd, J = 1.6 Hz, 16.0 Hz, 1H, 14-H), 7.18–7.36 
(m, 5H, Ph-H); 13C{1H} NMR (100 MHz, CDCl3) δ (ppm) = 14.1 (C-1), 17.9 (C-2), 27.4 (C-10), 
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28.4 (C-3), 29.8 (C-11), 53.7 (C-8), 58.8 (C-4), 63.1 (C-5), 71.3 (C-12), 73.1 (C-9), 126.5 (C-m-
Ph), 127.6 (C-p-Ph), 128.5 (C-o-Ph), 129.3 (C-13), 130.4 (C-14), 136.5 (C-i-Ph), 154.2 (C-6), 
174.2 (C-7); FT-IR (ATR): ν~ = 3452 (w, b), 3027 (w), 2967 (w), 2875 (w), 1773 (m), 1750 (m), 
1686 (vs), 1601 (w), 1494 (w), 1466 (w), 1450 (w), 1363 (s), 1300 (m), 11253 (m), 1200 (s), 1143 
(m), 1097 (m), 1059 (m), 1027 (m), 973 (m), 915 (w), 856 (w), 770 8w), 750 (m), 731 (w), 697 
(m), 620 (w), 607 (w), 526 (w), 486 (w), 425 (w) cm–1; HRMS (ESI) m/z: [M+Na]+ Calcd for 
C20H27NaNO5Na 384.1781; Found 384.1800. 
General Procedure for the Synthesis of Mosher Esters (GP2). To a solution of the respective 
alcohol 13 or 14 (1.0 equiv) in abs. CH2Cl2 (2 mL) at 0 °C were successively added anhyd pyridine 
(2.2 equiv), a solution of (R)- or (S)-MTPACl (1.3 equiv) in abs. CH2Cl2 (1 mL) and DMAP (0.55 
equiv). The reaction mixture was slowly warmed to room temperature and stirred overnight. The 
solvent was removed under vacuum, and the residue was purified by chromatography on SiO2. 
(1R,2E)-1-{2-[(4S)-4-Isopropyl-2-oxo-1,3-oxazolidin-3-yl]-2-oxoethyl}-3,7-dimethylocta-2,6-
dienyl (2S)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoate [(S)-15a]. Purification by chroma-
tography (PE/EtOAc 6 : 1) gave (S)-15a (27.5 mg, 0.05 mmol, 85%, purity 90% 1H NMR) as a 
colorless oil. Rf = 0.34. 1H NMR (400 MHz, CDCl3) δ (ppm) = 0.86 (d, J = 7.0 Hz, 3H, 5’-H or 
6’-H), 0.91 (d, J = 7.0 Hz, 3H, 5’-H or 6’-H), 1.59 (s, 3H, 10-H or 11-H), 1.66 (s, 3H, 10-H or 11-
H), 1.86 (s, 3H, 12-H), 1.96-2.11 (m, 4H, 6-H, 7-H), 2.30-2.41 (m, 1H, 4’-H), 3.16 (dd, J = 
17.1 Hz, 3.7 Hz, 1H, 2-H), 3.44 (dd, J = 17.1 Hz, 9.4 Hz, 1H, 2-H), 3.52 (s, 3H, OCH3), 4.16-4.26 
(m, 2H, 3’-H), 4.33-4.39 (m, 1H, 2’-H), 5.03-5.09 (m, 2H, 4-H, 8-H), 6.21 (td, J = 9.5 Hz, 3.7 Hz, 
1H, 3-H), 7.34-7.41 (m, 3H, m-H, p-H), 7.46-7.49 (m, 2H, o-H); 13C{1H} NMR (100 MHz, CDCl3) 
δ (ppm) = 14.7 (C6’), 17.1 (C-5’), 17.8 (C-12), 18.1 (C-10 or C-11), 25.8 (C-10 or C-11), 26.4 (C-
7), 29.8 (C-4’), 39.6 (C-6), 40.4 (C-2), 55.7 (OCH3), 58.7 (C-2’), 63.6 (C-3’), 70.5 (C-3), 120.5 
 36
(CF3), 122.6 (C-8), 123.6 (C-o), 124.2 (C-4), 127.7 (C-m), 128.3 (C-p), 132.1 (C-9), 132.6 (C-5), 
143.5 (C-i), 154.1 (C-1’), 165.6 (COO), 169.3 (C-1); FT-IR (ATR):  = 2960 (m), 2924 (m), 2854 
(w), 1782 (vs), 1746 (s), 1703 (s), 1488 (w), 1452 (w), 1452 (m), 1387 (s), 1301 (m), 1269 (s), 
1238 (s), 1169 (vs), 1121 (s), 1080 (m), 1018 (m), 991 (m), 920 (w), 831 (w), 766 (w), 719 (m), 
641 (w) cm–1; HRMS (ESI) m/z: [M+Na]+ Calcd for C28H36F3NO6Na 562.2387; Found 562.2372. 
(1R,2E)-1-{2-[(4S)-4-Isopropyl-2-oxo-1,3-oxazolidin-3-yl]-2-oxoethyl}-3,7-dimethylocta-2,6-
dienyl (2R)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoate [(R)-15a]. Purification by chroma-
tography (PE/EtOAc 6 : 1) gave (R)-15a (27.2 mg, 0.05 mmol, 84%, purity 95% 1H NMR) as a 
colorless oil. Rf = 0.35. 1H NMR (400 MHz, CDCl3) δ (ppm) = 0.84 (d, J = 6.9 Hz, 3H, 5’-H or 
6’-H), 0.88 (d, J = 7.9 Hz, 3H, 5’-H or 6’-H), 1.60 (s, 3H, 10-H or 11-H), 1.66 (s, 3H, 10-H or 11-
H), 1.87 (s, 3H, 12-H), 1.99-2.12 (m, 4H, 6-H, 7-H), 2.27-2.36 (m, 1H, 4’-H), 3.03 (dd, J = 
16.9 Hz, 3.8 Hz, 1H, 2-Ha), 3.49-3.54 (m, 1H, 2-Hb), 3.54 (s, 3H, OCH3), 4.07-4.22 (m, 3H, 2’-H, 
3’-H), 5.03-5.09 (m, 1H, 8-H), 5.23 (d, J = 9.6 Hz, 1H, 4-H), 6.26 (td, J = 9.5 Hz, 3.8 Hz, 1H, 3-
H), 7.33-7.39 (m, 3H, m-H, p-H), 7.49-7.54 (m, 2H, o-H); 13C{1H} NMR (100 MHz, CDCl3) δ 
(ppm) = 14.7 (C-5’ or C6’), 17.1 (C-5’ or C6’), 17.8 (C-12), 18.1 (C-10 or C-11), 25.8 (C-10 or 
C-11), 26.4 (C-7), 28.5 (C-4’), 39.6 (C-6), 40.1 (C-2), 55.6 (OCH3), 58.6 (C-2’), 63.6 (C-3’), 70.4 
(C-3), 120.6 (CF3), 123.5 (C-8), 124.3 (C-o), 127.6 (C-4), 128.3 (C-m), 129.5 (C-p), 132.2 (C-9), 
132.8 (C-5), 143.9 (C-i), 154.1 (C-1’), 165.4 (COO), 169.0 (C-1); FT-IR (ATR):  = 2964 (w), 
2925 (w), 2854 (w), 1780 (s), 1747 (s), 1703 (s), 1488 (w), 1451 (w), 1386 (s), 1258 (s), 1237 (s), 
1204 (s), 1167 (vs), 1120 (s), 1106 (s), 1080 (m), 1017 (s), 989 (s), 971 (s), 914 (m), 824 (w), 765 
(m), 731 (s), 717 (s), 697 (s), 642 (m), 579 (w), 553 (w), 510 (w), 442 (w) cm–1; HRMS (ESI) m/z: 
[M+Na]+ Calcd for C28H36F3NO6Na 562.2387; Found 562.2375. 
 37
(1R,2Z)-1-{2-[(4S)-4-Isopropyl-2-oxo-1,3-oxazolidin-3-yl]-2-oxoethyl}-3,7-dimethylocta-2,6-
dienyl (2S)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoate [(S)-15b]. Purification by chroma-
tography (PE/EtOAc 5 : 1) gave (S)-15b (22.7 mg, 0.04 mmol, 70%, purity 80% 1H NMR) as a 
colorless oil. Rf = 0.43. 1H NMR (400 MHz, CDCl3) δ (ppm) = 0.86 (d, J = 7.0 Hz, 3H, 5’-H or 
6’-H), 0.92 (d, J = 7.0 Hz, 3H, 5’-H or 6’-H), 1.61 (s, 3H, 10-H or 11-H), 1.66 (s, 3H, 10-H or 11-
H), 1.73 (s, 3H, 12-H), 2.04-2.12 (m, 1H, 7-H), 2.12-2.21 (m, 2H, 6-H), 2.32-2.42 (m, 1H, 4’-H), 
3.07 (dd, J = 17.4 Hz, 3.3 Hz, 1H, 2-H), 3.47 (dd, J = 17.4, 9.7 Hz, 1H, 2-H), 3.51 (s, 3H, OCH3), 
4.18-4.24 (m, 2H, 3’-H), 4.32-4.38 (m, 1H, 2’-H), 5.04-5.11 (m, 1H, 4-H), 5.11-5.16 (m, 1H, 8-
H), 6.16-6.24 (m, 1H, 3-H), 7.34-7.41 (m, 3H, m-H, p-H), 7.45-7.50 (m, 2H, o-H); 13C{1H} NMR 
(100 MHz, CDCl3) δ (ppm) = 14.3 (C-5’ or C-6’), 14.7 (C-5’ or C-6’), 17.8 (C-12), 18.1 (C-10 or 
C-11), 25.8 (C-10 or C-11), 26.6 (C-7), 28.8 (C-4’), 32.6 (C-6), 40.5 (C-2), 55.7 (OCH3), 58.7 (C-
2’), 63.6 (C-3’), 70.0 (C-3), 121.4 (CF3), 124.0 (C-o), 127.7 (C-4), 128.3 (C-m), 129.6 (C-p), 132.6 
(C-9), 132.8 (C-5), 143.3 (C-i), 154.1 (C-1’), 165.5 (COO), 169.3 (C-1); FT-IR (ATR):  = 2962 
(m), 2924 (m), 2854 (w), 1782 (vs), 1747 8s), 1702 (s), 1591 (w), 1487 (w), 1451 (w), 1387 (s), 
1270 (s), 1238 (s), 1206 (s), 1183 8vs), 1169 (vs), 1121 (s), 1107 (m), 1080 (m), 1019 (m), 991 
(m), 972 (m), 919 (w), 823 (w), 765 (w), 719 (m), 641 (w), 600 (w), 559 (w), 502 (w), 450 (w) 
cm–1; HRMS (ESI) m/z: [M+Na]+ Calcd for C28H36F3NO6Na 562.2387; Found 562.2358. 
(1R,2Z)-1-{2-[(4S)-4-Isopropyl-2-oxo-1,3-oxazolidin-3-yl]-2-oxoethyl}-3,7-dimethylocta-2,6-
dienyl (2R)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoate [(R)-15b]. Purification by chroma-
tography (PE/EtOAc 6 : 1) gave (R)-15b (25.9 mg, 0.05 mmol, 80%, purity 90% 1H NMR) as a 
colorless oil. Rf = 0.37. 1H NMR (400 MHz, CDCl3) δ (ppm) = 0.83 (d, J = 7.0 Hz, 3H, 5’-H or 
6’-H), 0.89 (d, J = 7.0 Hz, 3H, 5’-H or 6’-H), 1.61 (s, 3H, 10-H or 11-H), 1.65 (s, 3H, 10-H or 11-
H), 1.76 (s, 3H, 12-H), 2.02-2.22 (m, 4H, 6-H, 7-H), 2.27-2.38 (m, 1H, 4’-H), 2.94 (dd, J = 
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17.2 Hz, 3.4 Hz, 1H, 2-H), 3.54 (s, 3H, OCH3), 3.50-3.59 (m, 1H, 2-H), 4.05-4.20 (m, 3H, 2’-H, 
3’-H), 5.10-5.16 (m, 1H, 8-H), 5.24 (d, J = 9.8 Hz, 1H, 4-H), 6.27 (td, J = 9.8 Hz, 3.4 Hz, 3-H), 
7.35-7.38 (m, 3H, m-H, p-H), 7.49-7.53 (m, 2H, o-H); 13C{1H} NMR (100 MHz, CDCl3) δ (ppm) 
= 14.7 (C-5’ or C6’), 17.1 (C-5’ or C6’), 17.8 (C-12), 18.1 (C-10 or C-11), 25.8 (C-10 or C-11), 
26.6 (C-7), 28.5 (C-4’), 32.6 (C-6), 40.2 (C-2), 55.6 (OCH3), 58.6 (C-2’), 63.6 (C-3’), 70.0 (C-3), 
121.4 (CF3), 123.9 (C-o), 127.7 (C-4), 128.3 (C-m), 129.4 (C-p), 132.4 (C-9), 132.9 (C-5), 143.6 
(C-i), 154.1 (C-1’), 165.3 (COO), 168.9 (C-1); FT-IR (ATR):  = 2965 (w), 2925 (w), 2854 
(w)1780 (vs), 1748 (s), 1703 (s), 1487 (w), 1451 (w), 1386 (s), 1237 (s), 1168 (vs), 1120 (s), 1106 
(s), 1080 (m), 1018 (s), 989 (s), 971 8s), 917 (w), 825 (w), 765 (m), 718 (s), 697 (m), 642 (w), 581 
(w), 553 8w), 507 (w), 452 (w) cm–1; HRMS (ESI) m/z: [M+Na]+ Calcd for C28H36F3NO6Na 
562.2387; Found 562.2399. 
(1S,2E)-1-{(1R)-2-[(4S)-4-Isopropyl-2-oxo-1,3-oxazolidin-3-yl]-1-methyl-2-oxoethyl}-3,7-di-
methylocta-2,6-dienyl (2S)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoate [(S)-16a]. Purification 
by chromatography (PE/EtOAc 6 : 1) gave (S)-16a (29.2 mg, 0.05 mmol, 88%, purity 90% 1H 
NMR) as a colorless oil. Rf = 0.28. 1H NMR (400 MHz, CDCl3) δ (ppm) = 0.79 (d, J = 6.9 Hz, 3H, 
5’-H or 6’-H), 0.87 (d, J = 6.9 Hz, 3H, 5’-H or 6’-H), 1.23 (d, J = 6.8 Hz, 3H, 13-H), 1.59 (s, 3H, 
10-H or 11-H), 1.65 (s, 3H, 10-H or 11-H), 1.84 (s, 3H, 12-H), 1.94-2.09 (m, 5H, 6-H, 7-H), 2.15-
2.23 (m, 1H, 4’-H), 2.15-2.23 (m, 1H, 2-H), 3.55 (s, 3H, OCH3), 4.14-4.28 (m, 2H, 2’-H, 3’-H), 
4.38-4.44 (m, 1H, 3’-H), 5.02-5.06 (m, 1H, 8-H), 5.09 (dd, J = 9.6 Hz, 0.8 Hz, 1H, 4-H), 5.99 (dd, 
J = 9.6 Hz, 7.1 Hz, 1H, 3-H), 7.34-7.40 (m, 3H, m-H, p-H), 7.45-7.51 (m, 2H, o-H); 13C{1H} NMR 
(100 MHz, CDCl3) δ (ppm) = 13.2 (C-13), 14.3 (C-5’ or C-6’), 14.5 (C-5’ or C-6’), 17.2 (C-12), 
17.8 (C-10 or C-11), 18.0 (C-10 or C-11), 25.8 (C-7), 26.4 (C-4’), 28.4 (C-6), 39.8 (C-2), 41.9 
(OCH3), 55.7 (2’), 58.6 (C-3’), 63.2 (C-3), 75.3 (C(OMe)CF3), 119.4 (CF3), 122.6 (C-8), 123.7 
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(C-o), 124.2 (C-4), 127.6 (C-m), 128.4 (C-p), 129.6 (C-9), 132.4 (C-5), 144.5 (C-i), 153.8 (C-1’), 
165.9 (COO), 173.1 (C-1); FT-IR (ATR):  = 2965 (w), 2925 (w), 2855 (w), 1778 (s), 1744 (s), 
1700 (s), 1488 (w), 1452 (m), 1385 (s), 1299 (m), 1260 (s), 1229 (s), 1184 (vs), 1120 (s), 1104 (s), 
1081 (m), 1056 (m), 1014 (vs), 990 (s), 965 (m), 910 (s), 803 (m), 765 (m), 731 (vs), 719 (vs), 697 
(s), 648 (m), 550 (w), 521 (w), 445 (w), 411 (w) cm–1; HRMS (ESI) m/z: [M+Na]+ Calcd for 
C29H38F3NO6Na 576.2543; Found 576.2560. 
(1S,2E)-1-{(1R)-2-[(4S)-4-Isopropyl-2-oxo-1,3-oxazolidin-3-yl]-1-methyl-2-oxoethyl}-3,7-di-
methylocta-2,6-dienyl (2R)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoate [(R)-16a]. Purification 
by chromatography (PE/EtOAc 6 : 1) gave (R)-16a (28.9 mg, 0.05 mmol, 87%, purity: 90% 1H 
NMR) as a colorless oil. Rf = 0.26. 1H NMR (400 MHz, CDCl3) δ (ppm) = 0.81 (d, J = 6.9 Hz, 3H, 
5’-H or 6’-H), 0.88 (d, J = 7.1 Hz, 5’-H or 6’-H), 1.08 (d, J = 6.8 Hz, 13-H), 1.58 (s, 3H, 10-H or 
11-H), 1.64 (s, 3H, 10-H or 11-H), 1.83 (s, 3H, 12-H), 1.96-2.11 (m, 5H, 6-H, 7-H), 2.15-2.25 (m, 
1H, 4’-H), 3.54 (s, 3H, OCH3), 4.15-4.26 (m, 2H, 2’-H, 3’-H), 4.34-4.45 (m, 1H, 3’-H), 4.98-5.07 
(m, 1H, 8-H), 5.24 (d, J = 9.7 Hz, 1H, 4-H), 5.96 (dd, J = 9.5 Hz, 8.3 Hz, 1H, 3-H), 7.33-7.41 (m, 
3H, m-H, p-H), 7.49-7.55 (m, 2H, o-H); 13C{1H} NMR (100 MHz, CDCl3) δ (ppm) = 13.4 (C-13), 
14.3 (C-5’ or C-6’), 14.5 (C-5’ or C-6’), 17.2 (C-12), 17.8 (C-10 or C-11), 18.0 (C-10 or C-11), 
25.8 (C-7), 26.4 (C-4’), 28.4 (C-6), 39.8 (C-2), 41.9 (C-OCH3), 55.6 (C-2’), 58.6 (C-3’), 63.2 (C-
3), 75.2 (C(OMe)CF3), 123.6 (CF3), 124.3 (C-8), 127.4 (C-o), 128.4 (C-4), 129.6 (C-m), 132.2 (C-
p), 132.7 (C-5), 144.9 (C-i), 153.8 (C-1’), 165.8 (COO), 173.5 (C-1); FT-IR (ATR):  = 2964 (w), 
2924 (w), 2853 (w), 1778 (s), 1746 (s), 1699 (s), 1488 (w), 1452 (m), 1384 (s), 1299 (m), 1268 
(s), 1229 (s), 1168 (vs), 1120 (s), 1104 (s), 1081 (m), 1055 (m), 1014 (vs), 989 (s), 964 (m), 932 
(m), 910 (s), 805 (m), 765 (m), 731 (vs), 719 (vs), 697 (s), 648 (m), 577 (w), 553 (w), 520 (w), 
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444 (w), 414 (w) cm–1; HRMS (ESI) m/z: [M+Na]+ Calcd for C29H38F3NO6Na 576.2543; Found 
562.2542. 
(1S,2Z)-1-{(1R)-2-[(4S)-4-Isopropyl-2-oxo-1,3-oxazolidin-3-yl]-1-methyl-2-oxoethyl}-3,7-di-
methylocta-2,6-dienyl (2S)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoate [(S)-16b]. Purification 
by chromatography (PE/EtOAc 5 : 1) gave (S)-16b (28.2 mg, 0.05 mmol, 85%, purity 90% 1H 
NMR) as a colorless oil. Rf = 0.38. 1H NMR (400 MHz, CDCl3) δ (ppm) = 0.80 (d, J = 6.9 Hz, 3H, 
5’-H or 6’-H), 0.87 (d, J = 7.4 Hz, 5’-H or 6’-H), 1.23 (d, J = 6.8 Hz, 3H, 13-H), 1.64 (s, 3H, 10-
H or 11-H), 1.69 (s, 3H, 10-H or 11-H), 1.88 (s, 3H, 12-H), 2.02-2.33 (m, 5H, 4’-H, 6-H, 7-H), 
3.55 (s, 3H, OCH3), 4.13-4.29 (m, 2H, 2’-H, 3’-H), 4.37-4.45 (m, 1H, 3’-H), 5.10 (dd, J = 23.9, 
7.9 Hz, 4-H), 5.13-5.22 (m, 1H, 8-H), 6.03 (dd, J = 9.7, 7.4 Hz, 1H, 3-H), 7.34-7.41 (m, 3H, m-H, 
p-H), 7.46-7.50 (m, 2H, o-H); 13C{1H} NMR (100 MHz, CDCl3) δ (ppm) = 13.5 (C-13), 14.3 (C-
5’, C-6’), 17.7 (C-12), 18.1 (C-10, C-11), 25.8 (C-7), 26.5 (C-4’), 28.3 (C-6), 29.7 (C-2), 41.9 
(OCH3), 55.7 (C-2’), 58.6 (C-3’), 63.1 (C-3), 74.7 (C(OMe)CF3), 120.2 (CF3), 124.2 (C-8), 127.7 
(C-o), 128.3 (C-4), 129.6 (C-m), 132.0 (C-p), 132.4 (C-5), 144.6 (C-i), 153.8 (C-1’), 165.8 (COO), 
173.6 (C-1); FT-IR (ATR):  = 2965 (m), 2925 (m), 2876 (w), 2854 (w), 1779 (vs), 1745 (s), 1700 
(s), 1488 (w), 1452 (m), 1384 (s), 1300 (m), 1261 (s), 1232 (s), 1184 (vs), 1121 (s), 1105 (s), 1081 
(m), 1056 (m), 1014 (s), 990 (s), 965 (m), 909 (m), 803 (m), 765 (m), 731 (s), 718 (s), 697 (m), 
648 (w), 517 (w), 449 (w), 412 (w) cm–1; HRMS (ESI) m/z: [M+Na]+ Calcd for C29H38F3NO6Na 
576.2543, found 562.2538. 
(1S,2Z)-1-{(1R)-2-[(4S)-4-Isopropyl-2-oxo-1,3-oxazolidin-3-yl]-1-methyl-2-oxoethyl}-3,7-di-
methylocta-2,6-dienyl (2R)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoate [(R)-16b]. Purification 
by chromatography (PE/EtOAc 5 : 1) gave (R)-16b (28.2 mg, 0.05 mmol, 88%, purity 90% 1H 
NMR) as a colorless oil. Rf = 0.40. 1H NMR (400 MHz, CDCl3) δ (ppm) = 0.81 (d, J = 6.8 Hz, 3H, 
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5’-H or 6’-H), 0.88 (d, J = 6.8 Hz, 5’-H or 6’-H), 1.07 (d, J = 6.8 Hz, 3H, 13-H), 1.62 (s, 3H, 10-
H or 11-H), 1.66 (s, 3H, 10-H or 11-H), 1.72 (s, 3H, 12-H), 2.03-2.11 (m, 2H, 7-H), 2.19-2.33 (m, 
3H, 4’-H, 6-H), 3.54 (s, 3H, OCH3), 4.15-4.26 (m, 3H, 3’-H), 4.37-4.42 (m, 1H, 2’-H), 5.12-5.18 
(m, 1H, 8-H), 5.27 (d, J = 9.9 Hz, 4-H), 6.02 (dd, J = 9.8 Hz, 8.4 Hz, 1H, 3-H), 7.32-7.41 (m, 3H, 
m-H, p-H), 7.49-7.56 (m, 2H, o-H); 13C{1H} NMR (100 MHz, CDCl3) δ (ppm) = 13.6 (C-13), 14.4 
(C-5’, C-6’), 17.7 (C-12), 18.1 (C-10 or C-11), 23.6 (C-10 or C-11), 25.8 (C-7), 26.5 (C-4’), 28.2 
(C-6), 32.7 (C-2), 42.0 (OCH3), 55.6 (C-2’), 58.6 (C-3’), 63.1 (C-3), 74.6 (C(OMe)CF3), 120.5 
(CF3), 124.1 (C-8), 127.5 (C-o), 128.4 (C-4), 129.6 (C-m), 132.1 (C-p), 132.8 (C-5), 145.0 (C-i), 
153.8 (C-1’), 165.7 (COO), 173.6 (C-1); FT-IR (ATR):  = 2965 (m), 2923 (m), 2877 (w), 2854 
(w), 1778 (vs), 1746 (s), 1699 (s), 1488 (w), 1452 (m), 1383 (s), 1299 (m), 1232 (vs), 1167 (vs), 
1120 (s), 1103 (s), 1080 (s), 1055 (s), 1014 (vs), 989 (vs), 964 (s), 931 (s), 909 (s), 803 (s), 765 
(m), 730 (s), 718 (vs), 697 (s), 648 (m), 595 (w), 554 (w), 509 (w), 450 (w), 408 (w) cm–1; HRMS 
(ESI) m/z: [M+Na]+ Calcd for C29H38F3NO6Na 576.2543; Found 576.2545. 
(1S,2E)-1-{2-[(4S)-4-Isopropyl-2-oxo-1,3-oxazolidin-3-yl]-1-methyl-2-oxoethyl}-3-phenylpro-
2-enyl (2S)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoate [(S)-16c]. Purification by chroma-
tography (PE/EtOAc 5 : 1) gave (S)-16c (41 mg, 0.076 mmol, 76%, purity 95% 1H NMR) as a 
colorless solid. Rf = 0.35. 1H NMR (500 MHz, CDCl3) δ (ppm) = 0.68 (d, J = 6.8 Hz, 3H, 5’-H or 
6’-H), 0.83 (d, J = 7.1 Hz, 3H, 5’-H or 6’-H), 1.26 (d, J = 6.9 Hz, 3H, 6-H), 2.18 (tt, J = 6.9 Hz, 
3.5 Hz, 1H, 4’-H), 3.61 (s, 3H, OMe), 4.16–4.30 (m, 3H, 2-H, 3’-H, 2-H), 4.43 (dt, J = 8.4 Hz, 
3.2 Hz, 1H, 2’-H), 6.02 (ddd, J = 6.8 Hz, 5.4 Hz, 1.1 Hz, 1H, 3-H), 6.12 (dd, J = 15.9 Hz, 7.0 Hz, 
1H, 4-H), 6.54 (d, J = 15.9 Hz, 1H, 5-H), 7.21–7.32 (m, 5H, o-H, m-H), 7.32–7.42 (m, 3H, p-H, 
m-H), 7.51 (dd, J = 7.1 Hz, 1.8 Hz, 2H, o-H); 13C{1H} NMR (126 MHz, CDCl3) δ (ppm) = 10.8 
(C-6), 13.1 (C-6’), 16.9 (C-5’), 27.1 (C-4’), 40.9 (C-2), 54.8 (OCH3), 57.6 (C-2’), 62.2 (C-3’), 76.3 
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(C-3), 83.5 (q, J = 27.7 Hz, C-8), 122.2 (q, J = 280 Hz, CF3), 122.7 (C-4), 125.7 (C-o), 126.4 (C-
o), 127.2 (C- p), 127.3 (C-m), 127.5 (C-m), 128.5 (C-p), 131.3 (C-i), 133.6 (C-5), 134.7 (C-i), 
152.9 (C-1’), 164.7 (C-7), 172.1 (C-1); FT-IR (ATR):  = 2965 (w), 2254 (vw), 1773 (s), 1747 (s) 
1700 (s), 1488 (w), 1451 (w), 1360 (m), 1299 (w), 1249 (m), 1228 (m), 1167 (s), 1120 (m), 1103 
(m), 1081 (w), 1056 (w), 1014 (m), 989 (m), 966 (m) 909 (m), 834 (vw), 804 (w), 729 (s), 718 (s), 
694 (s), 648 (w), 510 (vw), 459 (vw), 439 (vw) cm–1; HRMS (ESI) m/z: [M+Na]+ Calcd for 
C28H30F3NO6Na 556.1917; Found 556.1931. 
(1S,2E)-1-{2-[(4S)-4-Isopropyl-2-oxo-1,3-oxazolidin-3-yl]-1-methyl-2-oxoethyl}-3-phenylpro-
2-enyl (2R)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoate [(R)-16c]. Purification by chroma-
tography (PE/EtOAc 5 : 1) gave (R)-16c (45 mg, 0.084 mmol, 84%, purity 90% 1H NMR) as a 
colorless solid. Rf = 0.35. 1H NMR (500 MHz, CDCl3) δ (ppm) = 0.65 (d, J = 6.8 Hz, 3H, 5’-H or 
6’-H), 0.81 (d, J = 7.1 Hz, 3H, 5’-H or 6’-H), 1.13 (d, J = 6.8 Hz, 3H, 6-H), 2.19 (qd, J = 7.0 Hz, 
3.6 Hz, 1H, 4’-H), 3.54 (s, 3H, OMe), 4.17 (dd, J = 9.1 Hz, 3.0 Hz, 1H, 2-H), 4.20–4.28 (m, 2H, 
3’-H), 4.40 (dt, J = 8.3 Hz, 3.2 Hz, 1H, 2’-H), 5.97 (ddd, J = 7.6 Hz, 6.5 Hz, 0.9 Hz, 1H, 3-H), 
6.26 (dd, J = 16.0 Hz, 7.6 Hz, 1H, 4-H), 6.74 (d, J = 15.9 Hz, 1H, 5-H), 7.22–7.45 (m, 8H, o-H, 
m-H, p-H), 7.48–7.56 (m, 2H, o-H); 13C{1H} NMR (126 MHz, CDCl3) δ (ppm) = 11.3 (C-6), 13.1 
(C-6’), 16.9 (C-5’), 27.1 (C-4’), 40.9 (C-2), 54.5 (OCH3) 57.6 (C-2’), 62.2 (C-3’), 76.8 (C-3), 83.5 
(q, J = 27.7 Hz, C-8),122.4 (q, J = 280 Hz, CF3) 122.8 (C-4), 125.7 (C-o), 126.4 (C-o), 127.3 (C-
p), 127.4 (C-m), 127.6 (C-m), 128.6 (C-p), 131.3 (C-i), 134.5 (C-5), 134.6 (C-i), 152.8 (C-1’), 
164.7 (C-7), 172.0 (C-1); FT-IR (ATR):  = 2964 (w), 2257 (vw), 2165 (vw), 1774 (s), 1749 (s), 
1700 (s), 1488 (w), 1451 (w), 1386 (m), 1299 (m), 1230 (s), 1168 (s), 1120 (s) 1104 (s), 1081 (m), 
1056 (w), 1014 (s), 988 (s), 966 (s), 909 (s), 834 (vw), 803 (w), 729 (s), 694 (s), 648 (m), 556 
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(vw), 518 (w), 488 (w), 437 (vw) cm–1; HRMS (ESI) m/z: [M+Na]+ Calcd for C28H30F3NO6Na 
556.1917; Found 556.1928. 
(2S,3S,4E)-2,5,9-Trimethyldeca-4,8-diene-1,3-diol [(E)-17]. To a solution of (E)-14a (100 mg, 
0.30 mmol) in abs. THF/abs. MeOH (5 : 0.05 mL) at 0 °C was added dropwise LiBH4 (4 M in 
THF, 222 μL, 0.89 mmol), and the reaction mixture was stirred for 3 h. A satd solution of NaHCO3 
(10 mL) was added, the layers were separated, and the aqueous layer was extracted with EtOAc 
(3×15 mL). The combined organic layers were dried (MgSO4) and concentrated under vacuum. 
The residue was purified by chromatography on SiO2 (PE/EtOAc  2 : 1) to give (E)-17 (40.2 mg, 
0.19 mmol, 64%, 1H NMR purity >95%) as a colorless oil. Rf = 0.19. 20D]α[ = +65.2 (c = 1.0 in 
CH2Cl2); 1H NMR (400 MHz, CDCl3) δ (ppm) = 0.86 (d, J = 7.0 Hz, 3H, 11-H), 1.59 (s, 6H, 10-
H, 13-H), 1.66 (s, 3H, 12-H), 1.85-1.99 (m, 1H, 2-H), 1.98-2.16 (m, 4H, 6-H, 7-H), 2.52 (s, 2H, 
OH), 3.57 (dd, J = 10.8 Hz, 4.6 Hz, 1H, 1-Ha), 3.68 (dd, J = 10.7 Hz, 7.6 Hz, 1H, 1-Hb), 4.50 (dd, 
J = 9.0 Hz, 4.1 Hz, 1H, 3-H), 4.99-5.11 (m, 1H, 8-H), 5.29 (dd, J = 9.0 Hz, 1.1 Hz, 1H, 4-H); 
13C{1H} NMR (100 MHz, CDCl3) δ (ppm) = 11.9 (C-12), 16.8 (C-10 or C-13), 17.8 (C-10 or C-
13), 25.8 (C-11), 26.5 (C-7), 39.9 (C-6), 40.6 (C-2), 66.3 (C-1), 71.9 (C-3), 124.0 (C-8), 124.9 (C-
4), 131.9 (C-9), 139.4 (C-5); FT-IR (ATR):  = 3338 (m), 2965 (m), 2921 (m), 2064 (w), 1731 
(w), 1669 (w), 1669 (w), 1449 (m), 1376 (m), 1261 (w), 1106 (m), 1082 (m), 1030 (s), 970 (s), 
816 (w), 562 (w), 447 (w), 419 (w) cm–1; MS (EI) m/z: [M+] Calcd for C13H24O2 212.1776; Found 
212.1776. 
(2S,3S,4Z)-2,5,9-Trimethyldeca-4,8-diene-1,3-diol [(Z)-17]. As described above from (Z)-14a 
(100 mg, 0.30 mmol) and LiBH4 (4 M in THF, 222 μL, 0.89 mmol), chromatography (PE/EtOAc 
2 : 1), yield: 38.1 mg, 0.18 mmol, 60%, 1H NMR purity >95%, colorless oil. Rf = 0.22. 20D]α[ = 
+68.6 (c = 1.2 in CH2Cl2); 1H NMR (400 MHz, CDCl3) δ (ppm) = 0.88 (d, J = 7.0 Hz, 3H, 11-H), 
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1.59 (s, 3H, 10-H or 13-H), 1.67 (s, 3H, 10-H or 11-H), 1.75 (s, 3H, 12-H), 1.81-1.96 (m, 1H, 2-
H), 1.98-2.20 (m, 4H, 6-H, 7-H), 2.39 (s, 2H, OH), 3.52-3.64 (m, 1H, 1-H), 3.68 (dd, J = 10.8 Hz, 
7.2 Hz, 1H, 1-H), 4.47 (dd, J = 9.3 Hz, 4.3 Hz, 1H, 3-H), 5.02-5.15 (m, 1H, 8-H), 5.34 (d, J = 9.2 
Hz, 1H, 4-H); 13C{1H} NMR (100 MHz, CDCl3) δ (ppm) = 11.7 (C-12), 17.6 (C-11), 23.5 (C-10 
or C-13), 25.6 (C-10 or C-13), 26.5 (C-7), 32.2 (C-6), 40.2 (C-2), 66.3 (C-1), 71.2 (C-3), 123.9 
(C-8), 125.5 (C-4), 132.4 (C-9), 139.9 (C-5); FT-IR (ATR):   = 3346 (m), 2965 (m), 2916 (m), 
2876 (m), 1994 (w), 1972 (w), 1726 (w), 1665 (w), 1449 (m), 1376 (m), 1262 (w), 1104 (m), 1080 
(m), 1031 (s), 968 (s), 857 (w), 820 (w), 731 (w), 596 (m), 453 (w) cm–1; MS (EI) m/z: [M+] Calcd 
for C13H24O2 212.1776; Found 212.1768. 
(4S,5S)-4-[(1E)-2,6-Dimethylhepta-1,5-dienyl]-2,2,5-trimethyl-1,3-dioxane [(E)-18]. To a so-
lution of (E)-17 (20 mg, 0.09 mmol) in abs. acetone (1 mL) at room temperature were added 
dimethoxypropane (99.0 μL, 83.4 mg, 0.8 mmol) and PPTS (1 mg, 3.0 µmol). The reaction 
mixture was stirred for 3 h, and then the solvent was removed under vacuum. The residue was 
purified by chromatography on SiO2 (PE/EtOAc 10 : 1 and 1 v/v Et3N) to give (E)-18 (20.5 mg, 
0.08 mmol, 90%, 1H NMR purity >95%) as a colorless oil. Rf = 0.38. 20D]α[ = +52.8 (c = 1.1 in 
CH2Cl2); 1H NMR (400 MHz, CDCl3) δ (ppm) = 1.11 (d, J = 6.9 Hz, 3H, 8-H), 1.42 (s, 6H, 7a-H, 
7b-H), 1.44-1.49 (m, 1H, 5-H), 1.50 (s, 3H, 7’-H or 9’-H), 1.66 (s, 3H, 7’-H or 9’-H), 1.67 (s, 3H, 
8’-H), 1.96-2.18 (m, 4H, 3’-H, 4’-H), 3.59 (dd, J = 11.5 Hz, 1.7 Hz, 1H, 6-H), 4.15 (dd, J = 
11.5 Hz, 2.9 Hz, 1H, 6-H), 4.75 (dd, J = 7.7 Hz, 2.8 Hz, 1H, 4-H), 5.02-5.13 (m, 1H, 5’-H), 5.21 
(dd, J = 7.7 Hz, 1.2 Hz, 1H, 1’-H); 13C{1H} NMR (100 MHz, CDCl3) δ (ppm) = 11.3 (C-8), 17.0 
(C-7’ or C-9’), 17.8 (C-7’ or C-9’), 19.3 (C-8), 25.8 (C-7a or C-7b), 26.5 (C-7a or C-7b), 29.9 (C-
3’), 32.9 (C-4’), 39.8 (C-5), 66.7 (C-6), 69.3 (C-4), 98.8 (C-2), 124.0 (C-5'), 124.2 (C-1’), 131.8 
(C-6’), 138.3 (C-2’); FT-IR (ATR):  = 3411 (w), 2965 (m), 2925 (m), 2858 (m), 2125 (w), 1671 
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(w), 1450 (m), 1378 (m), 1270 (m), 1239 (m), 1195 (m), 1166 (m), 1137 (m), 1102 (m), 1087 (m), 
1008 (s), 983 (m), 963 (m), 914 (m), 862 (m), 843 (m), 817 (m), 753 (w), 540 (w), 517 (m), 433 
(w) cm–1; MS (EI) m/z: [M+] Calcd for C16H28O2 252.2089; Found 252.2097. 
(4S,5S)-4-[(1Z)-2,6-Dimethylhepta-1,5-dienyl]-2,2,5-trimethyl-1,3-dioxane [(Z)-18]. As des-
cribed above, from (Z)-17 (20 mg, 0.09 mmol), dimethoxypropane (99.0 μL, 83.4 mg, 0.8 mmol) 
and PPTS (1 mg, 3.0 µmol), chromatography (PE/EtOAc 10 : 1 and 1 v/v Et3N), yield: 19.9 mg, 
0.08 mmol, 88%, 1H NMR purity >95%), colorless oil. Rf = 0.40. 20D]α[ = +57.7 (c = 1.1 in 
CH2Cl2); 1H NMR (400 MHz, CDCl3) δ (ppm) = 1.13 (d, J = 6.9 Hz, 3H, 8-H), 1.41 (s, 3H, 7a-H 
or 7b-H), 1.42-1.47 (m, 1H, 5-H), 1.49 (s, 3H, 7a-H or 7b-H), 1.61 (s, 3H, 7’-H or 9’-H), 1.68 (s, 
3H, 7’-H or 9’-H), 1.75 (s, 3H, 8’-H), 1.95-2.22 (m, 4H, 3’-H, 4’-H'), 3.59 (dd, J = 11.5 Hz, 1.7 
Hz, 1H, 6-H), 4.13 (dd, J = 11.5 Hz, 2.9 Hz, 1H, 6-H), 4.74 (dd, J = 8.2 Hz, 2.7 Hz, 1H, 4-H), 
5.04-5.17 (m, 1H, 5’-H), 5.24 (dd, J = 8.2 Hz, 1.1 Hz, 1H, 1’-H); 13C{1H} NMR (100 MHz, 
CDCl3) δ (ppm) = 11.3 (C-8’), 17.0 (C-7’ or C-9’), 17.8 (C-7’ or C-9’), 19.3 (C-8), 25.8 (C-7a or 
C-7b), 26.5 (C-7a or C-7b), 29.9 (C-4'), 32.9 (C-3'), 39.8 (C-5), 66.7 (C-6), 69.3 (C-4), 98.8 (C-
2), 124.0 (C-5'), 124.2 (C-1'), 131.8 (C-6'), 138.3 (C-2'); FT-IR (ATR):  = 3359 (w), 2962 (m), 
2925 (m), 2856 (m), 2168 (w), 2071 (w), 2037 (w), 2026 (w), 1734 (w), 1455 (m), 1377 (m), 1261 
(w), 1104 (w), 1034 (m), 967 (m), 512 (w), 451 (w), 422 (w), 407 (w) cm–1; MS (EI) m/z: [M+] 
Calcd for C16H28O2 252.2089; Found 252.2080. 
(4S)-4-Isopropyl-3-(3-methylbut-2-enoyl)-1,3-oxazolidin-2-one (23).31 To a solution of 22 
(2.00 g, 15.5 mmol) in THF (60 mL) at –78  °C was slowly added dropwise a 1.7 M solution of  
t-BuLi in n-pentane (9.70 mL, 16.5 mmol). Then 3-methylbut-2-enoyl chloride, which was 
prepared from 3,3-dimethylacrylic acid (1.65 g, 16.5 mmol) in abs. CH2Cl2 (15 mL) at 0  °C by 
dropwise addition of (COCl)2 (1.46 mL, 2.16 g, 17.0 mmol) over 5 min followed by stirring for 3 h 
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at 0 °C, removal of the solvent, repeated take up in CHCl3 (1 mL) and concentration under vacuum, 
was slowly added dropwise, the reaction mixture stirred at –78  °C for 2 h and allowed to warm to 
room temperature overnight. After cooling to 0  °C, a satd solution of NaHCO3–H2O (2 mL) was 
added followed by addition of a satd solution of NH4Cl–H2O (3 mL). The aqueous layer was 
extracted with CH2Cl2 (2 × 50 mL) and THF (2 × 30 mL). The combined organic layers were dried 
(MgSO4) and the solvent removed under vacuum. The residue was purified by column 
chromatography on SiO2 (PE/EtOAc 10:1) to give 23 (1.85 g, 8.77 mmol, 57%) as a yellow oil. Rf 
= 0.24. 1H NMR (500 MHz, CDCl3) δ (ppm) = 0.88 (d, J = 7.0 Hz, 3H, 1-H), 0.92 (d, J = 7.0 Hz, 
3H, 2-H), 1.99 (s, 3 H, 10-H), 2.17 (s, 3H, 11-H), 2.40 (d sept, J = 7.0 Hz, 3.9 Hz, 1H, 3-H), 4.19 
(dd, J = 9.0, 3.1 Hz, 1H, 5-Ha), 4.25 (dd, J = 9.0, 8.5 Hz, 1H, 5-Hb), 4.48 (ddd, J = 8.5, 3.9, 3.1 Hz, 
1H, 4-H), 6.95 (m, 1H, 8-H); 13C{1H} NMR (125 MHz, CDCl3) δ (ppm) = 14.7 (C-1), 18.1 (C-2), 
21.4 (C-10), 28.1 (C-11), 28.6 (C-3), 58.6 (C-5), 63.1 (C-4), 115.9 (C-8), 154.1 (C-9), 159.1 (C-
6), 165.1 (C-7); FT-IR (ATR): ν~ = 2965 (w), 2877 (w), 1772 (vs), 1679 (m), 1632 (m), 1487 (w), 
1447 (b), 1386 (m), 1362 (m), 1300 (w), 1256 (s), 1209 (m), 1185 (s), 1141 (w), 1121 (w), 
1101 (w), 1082 (w), 1056 (w), 1024 (w), 1005 (w), 977 (w), 851 (b), 775 (w), 754 (w), 715 (w), 
632 (w) cm–1; HRMS (ESI) m/z: [M+Na]+ Calcd for C11H17NO3Na 234.1101; Found 234.1109. 
(4S)-3-(2-Chloro-3-hydroxy-3-methylbutanoyl)-4-isopropyl-1,3-oxazolidin-2-one (20).31 To a 
solution of 23 (250 mg, 1.18 mmol) in CH2Cl2 (1 mL) were added Ca(OCl)2 (118 mg, 0.83 mmol) 
and H2O (2 mL). After cooling to 0 °C, glacial HOAc (0.95 mL, 99.5 mg, 1.66 mmol) was added 
with stirring and the reaction mixture stirred for a further 15 min prior to addition of CH2Cl2 (20 
mL) and H2O (30 mL). The layers were separated and the organic layer was successively washed 
with a half concd solution of NaHCO3–H2O (2 × 10 mL) and H2O (10 mL), dried (MgSO4) and 
the solvent removed under reduced pressure to give 20 (250 mg) as a (1:1) diastereomeric mixture 
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(denoted as a and b in NMR spectra), which could not be purified by chromatography. 1H NMR 
(400 MHz, CDCl3) δ (ppm) = 0.89–0.98 (m, 6H, 1a,b-H, 2a,b-H), 1.37 (a) + 1.38 (b) (s, s, 3H, 10-
H), 1.41 (b) + 1.44 (a) (s, s, 3H, 11-H), 2.34–2.47 (m, 1H, 3a,b-H), 4.25–4.32 (m, 1H, 5a,b-Ha), 
4.33–4.43 (m, 1H, 5a,b-Hb), 4.50–4.57 (m, 1H, 4a,b-H), 5.69 (b) + 5.74 (a) (s, s, 1H, 8-H); 13C{1H} 
NMR (100 MHz, CDCl3) δ (ppm) = 14.6 (C-1b), 14.7 (C-1a), 17.7 (C-2b), 17.8 (C-2a), 24.7 (C-
10a), 25.3 (C-10b), 27.5 (C-11b), 27.8 (C-11a), 28.0 (C-3b), 28.5 (C-3a), 58.4 (C-4a), 59.1 (C-8b), 
59.2 (C-8a), 59.3 (C-4b), 63.6 (C-5b), 63.8 (C-5a), 72.2 (C-9b), 72.7 (C-9a), 153.4 (C-6b), 153.9 (C-
6a), 168.7 (C-7a), 169.2 (C-7b); FT-IR (ATR): ν~ = 3507 (w, b), 2969 (w), 2876 (w), 1759 (m), 
1698 (vs), 1467 (w), 1358 (s), 1300 (m), 1260 (m), 1202 (s), 1123 (m), 1100 (m), 1057 (w), 1025 
(m), 972 (w), 930 (w), 892 (w), 878 (w), 848 (w), 814 (w), 763 (m), 737 (w), 709 (m), 633 (w), 
598 (w), 549 (w), 490 (w), 429 (w) cm–1. HRMS (ESI) m/z: [M+H]+ Calcd for C11H19ClNO3 
264.0997; Found 264.0995; HRMS (ESI) m/z: [M+Na]+ Calcd for C11H18ClNO4Na 286.0817; 
Found 286.0813. 
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